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ABSTRACT 
 The goal of this study was the dosimetric characterization of a mini-beam collimator on 
three clinically beam matched Varian iX linear accelerators.  Measurements of the beam quality 
(%DD(10)), peak-to-valley dose ratio (PVDR), collimator factor (𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 ), and relative output 
factor (𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 ) were carried out for 2 cm x 2 cm, 3 cm x 3 cm, 4 cm x 4 cm, and 5 cm x 5 cm 
mini-beam collimated 6 MV fields on each linear accelerator.  As well, Monte Carlo simulation of 
the mini-beam collimated fields were used to link the measurement results to a validated linear 
accelerator model.  The quality of the mini-beam collimated field was clinically equivalent to that 
of the open field.  Changes in the mini-beam collimated field in response to changes in both field 
size and collimator inclination were consistent across all three linear accelerators.  However, 
PVDR, collimator factors, and relative output factors varied in excess of the measurement 
uncertainty, revealing a difference in the mini-beam collimated fields of each linear accelerator.  
The change in PVDR was proportional to that of the collimator factor and relative output factor.  
The Monte Carlo simulations showed that variation in the full-width half-maximum of the linear 
accelerators’ electron beam incident on the Bremsstrahlung target correlated to the variation in 
collimator factor and PVDR across the accelerators.  These results demonstrate that while the mini-
beam collimated field varies across linear accelerators, the effect can be accounted for in the linear 
accelerator model, allowing the planning and delivery of mini-beam collimated fields using 
medical linear accelerators. 
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CHAPTER 1 
INTRODUCTION 
 
 Radiation oncology involves the use of ionizing radiation in the treatment of cancer.  The 
ionizations produced by high energy radiation can disrupt molecular structures. When incident on 
living cells, ionizing radiation is known to damage DNA, leading to errors in repair or replication.  
Rapidly multiplying cells, such as cancer cells, are more likely to replicate the damaged strand 
before it can be repaired [1].  These errors can render the cell non-viable, leading to a decrease in 
cell population when it is unable to multiply, or simply kill it outright.  However, the same effects 
occur in healthy cells, causing damage to surrounding tissue.  The trade-off between killing cancer 
cells and sparing healthy cells is quantified by the therapeutic index, a comparison of the likelihood 
of tumor control versus healthy cell death [2].  Increased therapeutic index is likely to improve 
patient outcomes, and is therefore a desirable feature in new or refined treatment methods. 
The goal of this project is the dosimetric characterization of a mini-beam collimator 
intended for use with medical linear accelerators.  The collimator is an attachment for linear 
accelerators used in external beam radiotherapy, which allows the use of spatial fractionation 
techniques by any treatment center.   
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1.1. External Beam Radiotherapy 
 Methods of delivering radiation to patients can be divided into external and internal 
radiotherapy, depending on the location of the source.  External beam radiotherapy involves the 
use of externally-generated radiation beams to deliver radiation to targets within the body.   
Medical linear accelerators (linacs) are used to generate radiation beams for use in radiation 
oncology.  Electrons are accelerated into a magnetic field generated by a bending magnet.  This 
magnet rotates the beam through 270o onto an aperture.  Only electrons at or near the selected 
energy will pass through the aperture, with the paths of the other electrons being bent too little or 
too much, striking the shielding in the accelerator treatment head.  The collimated electron beam 
is then incident upon either a Bremsstrahlung target, if being used to create a photon beam, or a 
scattering foil, if being used to create an electron beam.  This beam is shaped according to the 
treatment plan by a set of jaws and the multi-leaf collimators.  These components are located in a 
gantry, which rotates around a center point known as the isocenter.  This configuration allows for 
the delivery of radiation beams from multiple angles.  Figure 1.1 depicts a medical linear 
accelerator of this type.   
Since photons produced by Bremsstrahlung interaction have a range of energies, photon 
beam energies are specified by the accelerating potential of the electron beam, in units of peak 
kilovoltage (kV) or peak Megavoltage (MV).  The duration of the beam delivery is defined in 
terms of monitor units (MU), defined such that 1 MU beam-on time for a 10 cm x 10 cm field 
delivers 1 cGy to a point at the depth of maximum dose in water.  X-ray beams irradiate everything 
in the path, rather than only the target volume.  Treatments must account for this effect to maximize 
the therapeutic index. 
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Figure 1.1. A medical linear accelerator used to produce high energy X-rays. All major 
components are shown.  Image from Podgorsak 2005 [3], used with permission. 
 
1.2. Fractionation 
Several methods to increase the therapeutic index by reducing healthy cell death have been 
developed.  A category of these techniques are referred to as fractionation, splitting the delivery 
of radiation in some way to reduce the damage to healthy cells.  Temporal fractionation delivers 
the planned dose in multiple “fractions”, separated by a fixed period of time.  By splitting the 
delivery, the repair mechanisms of healthy cells have time to repair DNA damage.  This effect is 
not as significant in cancer cells; as mentioned above, DNA damage tends to propagate before the 
repair mechanisms can take effect, due to their more rapid reproduction [1]. Temporal fractionation 
is a commonly used and effective treatment method, but even greater benefits are sought via 
alternative methods. 
A less common, though long understood method is spatial fractionation.  Unlike beams 
intended to deliver a spatially-invariant dose across the field, spatial fractionation techniques 
deliver dosages in a non-uniform pattern.  One of the earliest spatial fractionation techniques was 
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known as GRID therapy [4], which delivers an array of centimeter scale pencil beams.  Originally 
used to limit normal tissue toxicity when irradiating deep targets, it fell out of favor with the 
development of medical linear accelerators.  However, in recent years, it has been revived for the 
purpose of reducing the volume of shallow bulky tumors.  GRID therapy can be delivered by 
conventional medical linear accelerators through the use of a specialized collimator [5, 6] or multi-
leaf collimation [7, 8].  These techniques have shown promise for the control of bulky tumours, 
but have limited application for treating smaller volumes. 
Another variant, micro-beam radiotherapy (MRT) [9, 10] makes use of synchrotron-
generated photon beams. MRT is delivered using an array of beams with an approximate full-
width-half-maximum of 25 – 75 μm with 100 – 400 μm spacing, as measured at the target surface 
[11].  The use of synchrotron-generated photons facilitates the fine control over beam energy and 
the spatial distribution of the micro-beam array.  MRT delivers extremely high doses to tightly 
defined regions.  Studies in rats have obtained promising results when examining the use of micro-
beams to treat brain lesions in rats [12, 13, 14, 15], achieving tumour control while inflicting 
minimal damage to healthy tissue around the directly-irradiated region, in what is called the 
“tissue-sparing effect” [16, 17, 18]. However, MRT has two major impediments to widespread 
use.  Generation of micro-beams requires a synchrotron, limiting the study or use of MRT to major 
centers.  As well, micro-beams are poorly suited for irradiating target volumes within the patient 
due to their low energy (approximately 200 kV).   
One possibility to overcome these limitations is the development of higher energy spatially 
fractionated beams, which are suited to irradiating deeper targets.  Increased beam energy also 
allows the delivery of this variety of spatially fractionated treatment using conventional medical 
linear accelerators, since higher energy beams can deliver the needed doses without requiring the 
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intensity of a synchrotron source.  Treatments of this type may make use of thicker beams, up to 
millimeter width, called mini-beams, in what is called mini-beam radiotherapy (MBRT).  Well-
defined kV mini-beams up to 0.68 mm in width have been observed to exhibit the same tissue-
sparing effect seen for micro-beams [19, 20, 21].  That MBRT may possess the radiobiological 
benefits of MRT without the accompanying limitations in accessibility makes it an intriguing 
treatment modality.  The use of an accessory to generate mini-beam arrays using a kV orthovoltage 
beam [22] was studied as a step towards widely accessible MBRT.  The study demonstrated the 
feasibility of the mini-beam collimator concept, but revealed limitations imposed by the low beam 
intensity of the orthovoltage machine. 
 
1.3. Mini-Beam Collimator Transferability Study 
 A mini-beam collimator for use with 6 MV photon beams has been designed and 
constructed at the Saskatoon Cancer Centre.  The collimator is intended to serve as an accessory 
for Varian iX linear accelerators. 
 The mini-beam collimator was initially commissioned for one of the medical linear 
accelerators at the Saskatoon Cancer Centre (SCC) [23].  The design process used Monte Carlo 
simulations to refine the collimator design.  After the collimator was constructed, the first step was 
dosimetric characterization to validate the design.  Dose profiles and relative output factors1 were 
measured for the mini-beam collimated field. 
 By comparing the simulated and measured results, the initial Monte Carlo model of the 
collimator and detectors was matched to the completed model.  However, to fulfill the intention of 
                                                          
1Both dose profiles and relative output factors are discussed in greater detail in Chapter 3.  
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making mini-beam radiotherapy widely available, the mini-beam collimated field must be shown 
to exhibit consistent dosimetric characteristics on different medical linear accelerators. 
In this work, dosimetric characterization of the mini-beam collimator was carried out on 
three clinically beam matched2 Varian accelerators operating at a nominal 6 MV photon beam 
mode.  The characterization process involved measuring the percent depth dose curves, dose 
profiles, and collimator factors on each linear accelerator.  The results were used to determine how 
the mini-beam collimated field varied between beam matched accelerators. 
Monte Carlo simulations of electron and photon transport were used to study the response 
of the collimated field output to variations in the linac parameters across linear accelerators.  By 
simulating the collimated beam incident on the detectors used in the study, specific aspects of the 
collimated field could be examined.  The simulation results were used to identify the cause of 
differences between the collimated outputs on different accelerators. 
 
1.4. Outline 
 This work covers the characterization and analysis of the mini-beam collimator on multiple 
linear accelerators.   
Chapter 2 covers the basics of ionizing radiation and its interactions with matter.  Directly-
ionizing radiation and indirectly-ionizing radiation are each introduced.  The process by which 
directly-ionizing radiation interacts with the medium is discussed, followed by the classification 
of these interactions.  The concept of stopping power is introduced.  Indirectly-ionizing radiation 
                                                          
2 The “beam matched” criterion is defined in Chapter 5. 
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is similarly described.  The three main interactions of indirectly-ionizing radiation: the 
photoelectric effect, scattering, and pair production are discussed. 
Chapter 3 discusses the measurement of radiation as used in the study. The key quantities 
are introduced.  An overview of cavity theory, the theoretical basis for dosimetry, is given, 
followed by a discussion of dosimeters and their use.  Finally, the specific measurements used in 
the study are described in detail. 
Chapter 4 introduces Monte Carlo simulation methods as applied to the study of radiation 
beams.  A brief history of Monte Carlo methods is given.  Next, the mechanics of Monte Carlo 
particle transport are described.  A discussion of the uncertainty analysis and management of 
Monte Carlo simulations follows.  Finally, the EGSnrc Monte Carlo simulation package is 
introduced and the individual simulation codes used in this study are described. 
Chapter 5 explains the procedure followed for the dosimetric characterization 
measurements of the mini-beam collimated field.  The experimental apparatus is described.  An 
outline of the procedure for each of the measurements is given.  The results of the measurements 
are presented and discussed. 
Chapter 6 describes the procedure used for Monte Carlo simulation of the mini-beam 
collimated field.  First, a description of the accelerator model used in the simulations is given.  A 
description of the process, with the inputs and outputs of each step follows.  The results of the 
simulations are presented and discussed. 
Chapter 7 provides recommendations regarding further use of the mini-beam collimator. 
Finally, a recommended characterization and QA procedure for the mini-beam collimator is 
presented.    
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CHAPTER 2 
IONIZING RADIATION 
 
Radiation is simply defined as emitted energy [24].  It can be in the form of energetic sub-
atomic particles, atoms, or photons.  Properly used, radiation can be a powerful tool in medicine.  
The effective use of radiation demands a sound knowledge of the underlying physics.  This chapter 
will discuss ionizing radiation and its interactions with matter as they relate to radiation oncology. 
Radiation is categorized by the nature of its interactions with a medium.  A clear division 
is between ionizing and non-ionizing radiation.  This distinction is based on the energy of the 
radiation.  Ionizing radiation is able to free atomic electrons from the atom, releasing them as free 
electrons and leaving behind an ion, a charged atom. 
In order to ionize an atom, sufficient energy must be delivered to overcome the energy of 
the bond between the electron and the nucleus, called the ionization or binding energy (EB).  Non-
ionizing radiation does not have sufficient energy to free electrons from an atom.  Excitation via 
interaction is possible, but the electron remains bound to the nucleus.  The selection of a dividing 
line is complicated by the range of ionization energies for different atoms, but a threshold of 10 
eV is considered adequate for radiobiological applications [24, 25].   
Ionizing radiation can be further divided by the means of energy transfer to the medium.  
The two types are directly-ionizing radiation and indirectly-ionizing radiation. 
 
 
9 
 
2.1. Directly Ionizing Radiation 
Directly-ionizing radiation consists of energetic charged particles (e.g. electrons or 
protons) which deposit energy via Coulomb interactions with the atoms of the medium.  Electron 
interactions with the atoms of the medium are a key mechanism of energy deposition for all 
radiation therapy treatment modalities. 
 
2.1.1. Coulomb Interactions 
The mechanism by which charged particles transfer energy to atoms in the medium is based 
on Coulomb’s Law, which describes the force exerted by charged bodies on one another: 
𝑭𝐶𝑜𝑢𝑙 = 
𝑞𝑞′
4𝜋𝜀𝑜𝑟2
?̂?,                                                        (2.1)          
where FCoul is the force on the charge q due to charge q’, r is the position of charge q relative to 
charge q’, and εo is the permittivity of free space [26].   
The energy E required to move a charged particle against this force is found by integrating 
Equation 2.1 over the path of the particle.  Therefore, the energy lost by a particle of charge q 
moving from an arbitrarily large distance to a distance r from a particle of charge q’ is:  
𝐸 =
𝑞
4𝜋𝜀𝑜
∗
𝑞′
𝑟
.                                                          (2.2)          
All energy lost by the moving particle is transferred to the electric field between the 
particles [26].  If the second particle was an atomic electron, it may be excited or ejected from the 
atom when the energy in the field exceeds its excitation or ionization energy, respectively.  The 
moving particle is accelerated in a new direction by the Coulomb force, accounting for any energy 
not absorbed by the other particle. 
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Since the Coulomb force between charged particles is exerted at range, electrons lose 
energy in this manner at all times in the medium.  Furthermore, they are deflected by the 
interactions, resulting in a highly erratic path.  The trajectory of the interacting particles before and 
after the interaction are constrained by conservation of momentum such that: 
∑(𝑚𝒗)𝑖𝑛𝑖𝑡𝑖𝑎𝑙 =∑(𝑚𝒗)𝑓𝑖𝑛𝑎𝑙                                         (2.3)          
and 
(𝑚𝑣)𝑖𝑛𝑖𝑡𝑖𝑎𝑙 =∑𝑚𝑗𝑣𝑗cos𝜃𝑗
𝑛
𝑗
,                                           (2.4)          
where m is the mass of the particle, v is the velocity of the particle, and 𝜃 is the angle between the 
trajectory of the incident particle and that of the emitted particle [24].  Most interactions involve 
only two particles, so momentum conservation may be described by: 
(𝑚𝑣)𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 𝑚1𝑣1 cos 𝜃 + 𝑚2𝑣2 cos𝜙,                              (2.5)          
where θ is the scattering angle of the incident particle and ø is the emission angle of the resultant 
particle.  In some interactions, particularly those with much more massive particles, (e.g. nuclei) 
the momentum lost by the electron will not be fully transferred to the other particle in the 
interaction.  In this event, the electron will emit Bremsstrahlung photons opposite the new 
trajectory of the scattered electron in order to conserve momentum. 
It is clear from Equations 2.3 – 2.5 that interactions between free and atomic electrons 
result in significant scattering, since the two electrons are of equal mass, and substantial changes 
in velocity must result if an atomic electron is freed.  Conversely, if the interaction is between an 
electron and a nucleus, the energy transfer causes negligible acceleration of the nucleus and only 
scatters the electron, due to the significant difference in mass.    
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2.1.2. Classification of Electron Interactions 
The type of interaction which takes place depends upon the impact parameter, b, the 
separation of the trajectory of the free electron and the central axis of the nucleus.  The size of b 
relative to the atomic radius, a, determines which particles interact and how much energy is 
transferred in the interaction.  Figure 2.1 depicts the three possible electron interactions. 
If b > a, a soft collision between the free electron and an atomic electron occurs.  Soft 
collisions transfer only a small amount of energy, often less than the amount necessary to free the 
atomic electron, and occur constantly in a medium [27]. 
If b ≈ a, a hard collision between the free electron and an atomic electron occurs.  These 
are direct collisions, resulting in much of the free electron’s energy being transferred to the atomic 
electron.  Hard collisions are highly likely to eject the atomic electron as a delta particle.  Despite 
occurring far less often than soft collisions, hard collisions transfer approximately half of the 
energy lost by the electron [27]. 
If b << a, a radiative interaction between the free electron and an atomic nucleus occurs.  
The electron scatters off the nucleus, changing its trajectory, while almost no effect on the nucleus 
can be observed.  The majority of radiative interactions are fully elastic, only resulting in a change 
in the free electron’s trajectory.  Non-elastic interactions release Bremsstrahlung photons. The 
energy of the photon is inversely proportional to the impact parameter [24].   
 
2.1.3. Stopping Power 
The rate of energy deposition in a medium by electron interactions can be characterized by 
the stopping power.  Stopping power is defined as the rate of energy lost, dE, per path length, dl. 
It can be expressed in terms of distance travelled, giving the linear stopping power, S: 
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(i) Soft collision.  The free electron is scattered, while an atomic electron is excited. 
 
(ii) Hard collision.  The free electron is scattered, while an atomic electron is ejected. 
(iii) Inelastic radiative interaction.  The electron is scattered off of the nucleus, releasing a 
Bremsstrahlung photon to conserve momentum. 
 
Figure 2.1.  Bohr representation of the three Coulomb electron-atom interactions. 
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𝑆 = −
𝑑𝐸
𝑑𝑙
  [
MeV
cm
],                                                         (2.6)          
or in terms of the mass thickness, giving the mass stopping power, 
𝑆
𝜌
 [29]: 
𝑆
𝜌
= −
1
𝜌
𝑑𝐸
𝑑𝑙
  [
MeV∗cm2
g
].                                                  (2.7)          
The total stopping power consists of two terms which correspond to collisional, Scol, and 
radiative, Srad, interactions.  Scol can be further divided into terms for hard and soft collisions, such 
that the total stopping power is given by: 
 𝑆𝑡𝑜𝑡 = + 𝑆𝑐𝑜𝑙
ℎ𝑎𝑟𝑑 + 𝑆𝑐𝑜𝑙
𝑠𝑜𝑓𝑡 + 𝑆𝑟𝑎𝑑,                                      (2.8)                                   
Generally, the collisional term predominates for low energy particles, and the radiative 
term predominates for higher energy particles.  The threshold for this transition is approximately 
800
𝑍
 MeV [24]. 
 The linear energy transfer (LET or LΔ), of a radiation beam is a restricted form of the linear 
stopping power.  LET is defined as the energy lost due to interactions which emit particles of 
energy less than a threshold (Δ) per unit length [3], and written as: 
𝐿∆ = (
𝑑𝐸
𝑑𝑙
)
∆
.                                                          (2.9)          
Δ serves to define the stopping power in terms of interactions which emit secondary 
particles which will deposit energy within a given distance from the interaction.  The size of this 
region is proportional to the threshold, which is selected to define a pertinent region of interest.  
This is of particular interest when considering biological effects.  High-LET radiation will deposit 
a great deal of energy in a small area, such as a cell nucleus.  This has been shown to increase the 
probability of severely damaging a DNA strand, greatly increasing the probability of cell death 
relative to low-LET radiation [1]. 
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2.2. Indirectly-Ionizing Radiation 
Indirectly-ionizing radiation consists of neutral particles (e.g. photons and neutrons).  
Energy from indirectly-ionizing radiation is deposited via a two step process.  First, the incident 
neutral particles interact with the atoms of the medium, freeing atomic electrons.  These freed 
electrons then deposit energy in the medium via Coulomb interactions, as previously described. 
A key difference between indirectly-ionizing and directly-ionizing radiation is that while 
directly ionizing radiation undergoes constant interactions in the medium, indirectly-ionizing 
radiation interacts with the medium only through direct and discrete interactions with atomic 
electrons.  Thus, the intensity (I) of an indirectly-ionizing radiation beam at distance d from the 
surface of medium is described by the attenuation relation: 
 𝐼(𝑑) = 𝐼𝑜𝑒
−𝜇𝑑,                                                      (2.10)          
where µ is the linear attenuation coefficient [cm−1].  The linear attenuation coefficient is a medium 
dependent quantity which describes the rate of energy loss due to interactions per unit length [24].  
Specific attenuation coefficients exist for the particular interactions: the photoelectric coefficient 
(τ) the Compton/Rayleigh scattering coefficients (σ) and the pair/triplet production coefficients 
(κ).  Thus, the total attenuation relates to the attenuation coefficients of each interaction such that: 
𝜇 = 𝜏 + 𝜎𝐶 + 𝜎𝑅 + 𝜅𝑃𝑃 + 𝜅𝑇𝑃 [cm−1].                                (2.11)          
Like stopping power, the linear attenuation coefficient can also be expressed in terms of mass, 
leading to the mass attenuation coefficient: 
𝜇𝑚 =
𝜇
𝜌
=
𝜏
𝜌
+
𝜎𝐶
𝜌
+
𝜎𝑅
𝜌
+
𝜅𝑃𝑃
𝜌
+
𝜅𝑇𝑃
𝜌
 [
cm2
g
].                           (2.12)          
The linear attenuation coefficient can also be expressed as a cross section per electron, 𝜇𝑒 , 
by: 
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𝜇𝑒 =
𝜇
𝑛
 [cm2]                                                     (2.13)          
and per atom, 𝜇𝑎 , by: 
𝜇𝑎 =
𝜇𝑍
𝑛
= 𝑍 𝜇𝑒  [cm
2],                                            (2.14)          
where n is the number density of the particle and Z is the atomic number of the atom.   
These cross sections represent the probability of the interaction occurring as the apparent 
size of the target to the photon.  The interaction cross sections, eτ or aτ for photoelectric interactions, 
eσ or aσ for Compton and Rayleigh scattering, and eκ or aκ for pair and triplet production, all 
contribute to the total interaction cross sections in the same way as the linear attenuation 
coefficients described in Equations 2.11 – 2.12 [24].  
Figure 2.2 depicts the relative interaction cross section for the photoelectric effect, 
scattering, and pair/triplet production.  The cross section for each interaction depends on the energy 
of the photon (E = hυ), resulting in different interactions predominating in different energy regions.  
In this way, all of the interactions contribute to the attenuation of the photon. 
 
2.2.1. Photoelectric Interactions 
For low energy photons, the photoelectric effect is the dominant interaction.  Photoelectric 
interactions are the total absorption of the photon by a tightly-bound electron (hυ ≈ EB).   
Conservation of energy and momentum require a third particle be present in the interaction to 
absorb recoil, hence the requirement that the electron by tightly bound [30].  Ionizing photoelectric 
interactions result in the emission of an electron with energy: 
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Figure 2.2. Plot of relative photon interaction cross sections for water [28]. 
 
𝐸𝑒 = ℎ𝜐 − 𝐸𝐵.                                                         (2.15)          
Tightly-bound electrons tend to occupy low energy states.  When they are emitted via 
ionization, a vacancy is produced, which will then be filled by a higher energy electron.  If the 
energy difference between the two states is larger than the lower state’s new ionization potential, 
the second electron will also be freed, becoming an “Auger electron.”  
The process will repeat until the binding energy is higher than the energy difference, in 
which case the excess energy is released as a fluorescent photon.  The total energy released by this 
“cascade” is equal to the energy of the initial photon [24]. A photoelectric interaction and 
subsequent Auger cascade are depicted in Figure 2.3. 
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Figure 2.3.  Bohr representation of a photoelectric interaction and Auger cascade. 
 
The photoelectrons are emitted at an angle (ø) off of the incident photon’s trajectory.  ø is 
non-deterministic, and is treated as a distribution of possible angles.  The width and mean of the 
distribution are inversely proportional to the incident photon energy.   
The cross section for photoelectric interaction with electrons, eτ, generally decreases with 
increasing photon energy, but exhibits spikes, called absorption edges, where the likelihood of 
interaction abruptly increases.  These edges correspond with electron shell binding energies, 
where total absorption is more probable.  For sufficiently high energy photons, τ is effectively 
zero, as seen in Figure 2.2.  Higher energy photons will exceed the binding energy of more 
electrons, making total absorption improbable. 
 
2.2.2. Compton and Rayleigh Scattering 
 At high photon energies, scattering becomes the dominant photon interaction.  Rayleigh 
scattering is the elastic collision of photons with tightly-bound electrons.  As an elastic collision, 
the photon loses no energy, but does transfer some momentum to the electron, changing the photon 
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(i) Photoelectric absorption   (ii) Auger electron emission   (iii) Fluorescent photon emission 
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trajectory and limiting the maximum depth achievable in the medium.  The scattering angle is 
approximated by: 
𝜃𝑅 ≅ 2sin
−1(
0.026√𝑍
3
(
ℎ𝜐
𝑚𝑒𝑐2
)
).                                          (2.16)          
Rayleigh scattering generally occurs at lower photon energies and higher atomic numbers than 
Compton scattering [24]. 
Compton scattering is an inelastic collision between a photon and a loosely-bound (EB << 
hυ) electron, resulting in the emission of a scattered photon and a recoil electron.  The energy of 
the scattered photon is given by: 
ℎ𝜐′ = 
ℎ𝜐𝑜
1 +
ℎ𝜐𝑜
𝑚𝑒𝑐2
(1 − 𝑐𝑜𝑠𝜃)
,                                           (2.17)         
where υ’ is the post scattering frequency of the photon, υo is the pre-scattering frequency of the 
photon, and θ is the scattering angle [31].   Thus, the resultant energy of the recoil electron is: 
𝐸𝑒 = ℎ𝜐𝑜 − ℎ𝜐
′ − 𝐸𝐵 .                                                 (2.18)         
Since Compton scattering must occur with loosely bound electrons, EB is small, and can be 
approximated as equal to zero.   
A Compton interaction is depicted in Figure 2.4.  The scattering angle θ and recoil angle ø 
relate to the initial photon trajectory as described for electron-electron interactions in Equations  
2.3 – 2.5. Note also that Equation 2.16 shows a proportional relationship between ℎ𝜐′ and θ when        
θ < 90o, and does not allow for θ ≥ 90o.  The scattering angle θ and electron recoil angle ø from 
the original photon trajectory relate to momentum conservation in the same manner as described 
for electron-electron interactions by Equations 2.3 – 2.5.     
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Figure 2.4.  Compton scattering of a photon with a loosely bound electron.  The photon is scattered 
at angle θ, and the electron is ejected from the atom at recoil angle ø. 
 
The interaction cross section for Compton scattering with of a free electron was derived 
from the Dirac theory of the electron by Oskar Klein and Yoshio Nishina [32].  Klein and Nishina’s 
formulation ( 𝜎𝑐
𝐾𝑁
𝑒 ) offered a refinement of the earlier models by way of the Klein-Nishina form 
factor, which reduced the calculated values to be more in line with experimental observation [30].  
As seen in Figure 2.2, 𝜎𝐶 is the dominant interaction cross section for photon energies between 
tens of keV and 10 MeV, dropping off outside this range.  Unlike the photoelectric effect and pair 
production, the scattering cross sections do not drop to zero at any photon energy, though they 
become extremely small in very low and very high energy regimes. 
 
2.2.3. Pair and Triplet Production 
 At photon energies above 1.022 MeV (2mec
2) pair production becomes possible. In pair 
production interactions the photon creates an electron-positron pair.  Since the total momentum of 
the electron-positron pair is less than that of the incident photon, pair production must occur near 
an atom, where a third particle can absorb the excess momentum.  This requirement raises the 
energy threshold for pair production by a factor dependent on the atomic mass (𝑚𝐴), such that: 
𝐸𝑡ℎ
𝑃𝑃 = 2𝑚𝑒𝑐
2 (1 +
𝑚𝑒𝑐
2
𝑚𝐴𝑐2
).                                       (2.19)          
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The additional energy requirement is slight, and decreases for heavier atoms.  
 When the third particle in the interaction is a nucleus, the interaction results in the emission 
of an electron-positron pair [27].  However, when the third particle is an electron, the recoil energy 
resulting from the momentum transfer may result in an ionization.  This is called triplet production.  
Only photons with energies above 2.044 MeV (4mec
2) can undergo triplet production.  Since an 
atomic electron is ejected in triplet production an Auger cascade may result. 
In pair and triplet production interactions the photon energy above the reaction threshold 
is transferred to the electron-positron pair, such that: 
𝐸𝑃𝑎𝑖𝑟 = ℎ𝜐 − 2𝑚𝑒𝑐
2 (1 +
𝑚𝑒𝑐
2
𝑚𝐴𝑐2
)                                (2.20)          
and 
𝐸𝑇𝑟𝑖𝑝𝑙𝑒𝑡 = ℎ𝜐 − 4𝑚𝑒𝑐
2 − 𝐸𝐵.                                     (2.21)          
As with Compton scattering, EB is generally negligible relative to the photon energy. 
 The energy is not transferred to the individual particles equally; any distribution of energies 
except 100% and 0% is possible, and no distribution is more probable than any other [24].  Both 
pair and triplet production are depicted in Figure 2.5. The emission angle of the electron and 
positron is non-deterministic and forward distributed [27]. 
 Since the positron is an antiparticle, it annihilates on contact with an electron.  In most 
interactions with these stopped positrons release two 511 keV photons travelling in opposing 
directions.  However, some positrons directly collide with atomic electrons before losing all of 
their energy.  If the atomic electron is tightly bound the excess momentum is absorbed by the 
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Figure 2.5.  Pair production and triplet production. 
 
nucleus, and a single photon (with ℎ𝜐 =  1.022 MeV +  𝐸𝐾
𝑒+) is emitted [24].  If the electron is 
loosely bound the momentum cannot be transferred to the nucleus, and is conserved by the two 
emitted photons, as described in Equations 2.3-2.5 [24]. 
 The pair/triplet production cross section (eκ) rises with increasing photon energy, causing 
pair/triplet production to become the dominant interaction at high photon energies.  It is also 
proportional to Z2, meaning that pair/triplet production is more prevalent for heavier elements [30]. 
  
 Photon energy is transferred to charged particles, which deposit the energy in the medium.  
This energy will cause the desired changes in the medium.  However, as described in Chapter 1, 
radiation damages cells indiscriminately, meaning that careful control of the energy deposited in 
the target and its surroundings is crucial.  A means of quantifying the energy delivered by radiation 
is necessary to achieve the intended outcomes. 
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CHAPTER 3 
DOSIMETRY 
 
As described in Chapter 2, a means of measuring the energy deposited in a medium by 
radiation is crucial for use in medical applications.  Dosimetry serves this purpose.   
This chapter will give an overview of dosimetry as it relates to radiation therapy.  The 
quantities of interest will be introduced, as will the theoretical basis for the use of dosimeters.  This 
will be followed with a brief overview of several varieties of dosimeters and the methods of 
operation.  Finally, the chapter will conclude with a description of dosimetric characterization of 
medical linear accelerator generated radiation beams. 
 
3.1. Dosimetric Quantities 
Dosimetry is the measurement of the energy deposited in a medium by radiation.  Several 
related quantities are used in the characterization process. 
 
3.1.1. Fluence 
 In dosimetry, both particle and energy fluence are considered.  Particle fluence is defined 
as the number of particles (dN) incident upon a cross-section normal to the path of the beam (dA) 
such that: 
Φ =
𝑑𝑁
𝑑𝐴
 [𝑚−2].                                                   (3.1)           
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Energy fluence is defined as the amount of energy (dE) incident upon a cross-section 
normal to the path of the beam dA: 
Ψ =
𝑑𝐸
𝑑𝐴
 [
𝐽
𝑚2
].                                                    (3.2)           
Note that particle fluence is related to energy fluence such that: 
Ψ = 𝐸 ∗ Φ.                                                         (3.3)           
 To more accurately represent a polyenergetic radiation beam the fluence can be expressed 
as a spectrum in terms of energy [25].  The particle fluence spectrum (𝛷𝐸) is defined as: 
ΦE =
𝑑Φ
𝑑𝐸
                                                           (3.4)           
and the energy fluence spectrum (𝛹𝐸) is defined as: 
ΨE =
𝑑Ψ
𝑑𝐸
.                                                          (3.5)           
 
3.1.2. Kerma 
The kinetic energy released per unit mass (kerma), is a measure of the energy transferred 
to secondary charged particles by indirectly ionizing radiation.   Kerma is defined as: 
𝐾 =
𝑑𝐸𝑡𝑟
𝑑𝑚
 [
𝐽
𝑘𝑔
].                                                      (3.6)           
where Etr is the energy transferred [25].  Kerma is measured in Gray (Gy), a derived unit defined 
in the International System of Units (SI) as Joules per kilogram. 
 As the resulting energy of the charged particles is the feature of interest in kerma, it is often 
more useful to ignore energy losses and consider only the energy which is immediately transferred 
to the medium.  Collisional kerma (𝐾𝑐𝑜𝑙) accounts for the energy transferred to charged particles 
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via photoelectric and scattering interactions, while ignoring the energy lost by the charged particles 
via Bremsstrahlung emission.  It is defined as: 
𝐾𝑐𝑜𝑙 = 𝐾(1 − 𝑔),                                                   (3.7)           
where g is the radiative fraction, the percentage of the total energy transferred to charged particles 
which is subsequently emitted via Bremsstrahlung radiation [25]. 
 Kerma is related to energy fluence by the attenuation coefficient (Equation 2.12) such that: 
𝐾𝑐𝑜𝑙 = Ψ ∗ 𝜇𝑚 = ∫ 𝑑𝐸 (ΨE)  ∗ 𝜇𝑚.
Emax
0
                               (3.8)         
For polyenergetic radiation beams, it is necessary to integrate 𝛹𝐸  over the full range of energies to 
find the energy released by a polyenergetic photon beam [3]. 
 
3.1.3. Absorbed Dose 
Absorbed dose is the energy imparted to the medium by charged particles per unit mass 
and is defined as:  
𝐷 =
𝑑?̅?
𝑑𝑚
  [
𝐽
𝑘𝑔
],                                                      (3.9)           
where 𝑑?̅? is the average energy deposited in the volume of mass dm.  Energy converted to mass 
via pair-production is not considered absorbed, and is not included in the definition.  Like kerma, 
absorbed dose is measured in Gy [29]. 
 Dose is related to electron fluence by the mass stopping power (Equation 2.7) such that: 
𝐷 = Φ ∗ (
𝑆𝑐𝑜𝑙
𝜌
) = ∫ 𝑑𝐸 (ΦE)  ∗ (
𝑆𝑐𝑜𝑙
𝜌
)
Emax
0
.                        (3.10)         
Note that this relation only holds where the range of Bremsstrahlung photons in the medium is 
much greater than the range of the secondary electrons [3].  This requirement exists to ensure that 
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the electron fluence incident upon the region of interest is the only mechanism for energy 
deposition.  
The distinction between dose and kerma arises because the charged particles freed by 
photons will travel some distance before depositing a non-negligible amount of energy, potentially 
leaving the region of interest.  Thus, the energy transferred to charged particles will not be entirely 
absorbed by the medium in the vicinity of the energy transfer.  This effect necessitates a “dose-
buildup” region when using high energy (>300 kV) indirectly ionizing radiation [33]. 
 
3.1.4. Charged Particle Equilibrium 
 The spatial separation between energy transfer to charged particles and energy deposition 
in the medium leads to an effect called charged particle equilibrium, where the energy entering 
and leaving a volume in the form of charged particles is equal.   
When a photon beam is incident upon a medium, such as water, collisional kerma is highest 
at the surface.  At the surface, photon energy fluence is at its peak in the medium, and both Ψ and 
Kcoll decrease with depth [3].  Thus, the largest number of electrons is freed at the surface.  
Similarly, they will have the greatest average energy of the electrons freed at any depth.  The freed 
electrons will travel a short distance in the water, depositing energy along the path.  At a depth 
approximately equal to the average range of the electrons freed at the surface the energy deposited 
reaches a peak.  This depth is called dmax, the depth of maximum dose.  Past dmax the dose decreases 
with depth, as more energy is deposited by delta electrons than is freed by photons to deposit 
energy at greater depth.  A plot of D and Kcoll against depth for an ideal photon beam is shown in 
Figure 3.1.  
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Figure 3.1. Depth dose and Kcoll for an ideal photon beam.   
 
The condition of true charged particle equilibrium is met only at the depth of peak dose 
(dmax).  However, a related condition called transient charged particle equilibrium is said to exist 
at depths greater than dmax where the rate of change in Kcoll is approximately equal to the rate of 
change in dose [35].   
 
3.2. Cavity Theory 
Thus far, descriptions have been given for a homogenous medium under irradiation.  To 
account for the effects of transitions between media, a method of correlating doses between regions 
with different stopping powers and attenuations is necessary.      
Consider a medium A containing a region B with different stopping power and attenuation 
coefficients.  The dose to a point in region B is known, but the dose to the equivalent point in 
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region A is not.  The ratio (sA,B) of the predicted dose to the same volume within a homogenous 
region A and the dose to region B follows from Equation 3.10 such that: 
𝑠𝐴,𝐵 =
𝐷𝐴
𝐷𝐵
=
ΦA ∗ (
𝑆𝑐𝑜𝑙
𝜌 )
𝐴
ΦB ∗ (
𝑆𝑐𝑜𝑙
𝜌 )
𝐵
= 
∫ 𝑑𝐸 (ΦE)A ∗ (
𝑆𝑐𝑜𝑙
𝜌 )
𝐴
Emax
0
∫ 𝑑𝐸 (ΦE)B ∗ (
𝑆𝑐𝑜𝑙
𝜌 )
𝐵
Emax
0
.                    (3.11)          
This relationship is the basis of cavity theory.  A “cavity” is simply a volume of some 
material within a medium composed of a different material (e.g. region B in the above example), 
as depicted in Figure 3.2.   Cavities are described by their size relative to the path length of the 
secondary particles being considered.  Small cavities are those smaller than the average path 
length.  They tend to have a minimal effect on particle fluence, and it is assumed that all absorbed 
dose in the cavity was deposited by particles produced outside the cavity [3].  As a result, many 
detectors are considered “small” when used with high energy beams, but this condition is difficult 
to achieve for low energy beams [36].  Large cavities are larger in all dimensions than the average 
path length of secondary particles.  Under this condition, it is assumed that all dose to the cavity 
was deposited by particles produced within the cavity [3].  While conceptually convenient for dose 
calculations, large cavities have a significant effect on the radiation fluence, and necessarily have 
poor spatial resolution. These considerations led to the formulation of several models for 
considering small cavities.  The Bragg-Gray [37] and Spencer-Attix [38] formulations for small 
cavities are notable. 
Bragg-Gray cavity theory assumes that the cavity is sufficiently small to cause no 
observable change in particle fluence.  In this case, Equation 3.11 becomes: 
𝑠𝐴,𝐵 = 
∫ 𝑑𝐸 (
𝑆𝑐𝑜𝑙
𝜌 )
𝐴
Emax
0
∫ 𝑑𝐸 (
𝑆𝑐𝑜𝑙
𝜌 )
𝐵
Emax
0
.                                                (3.12)          
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(i)                                                    (ii) 
Figure 3.2. A dosimeter inserted into a uniform medium A under irradiation by a photon beam.  (i) 
shows the homogenous medium, with the point of interest P labelled.  (ii) shows the medium with 
a cavity B of another material inserted around point P.  Cavity theory must be used to account for 
the impact of the cavity on the dose to P. 
 
Spencer-Attix cavity theory extends the Bragg-Gray model to account for the production 
of delta particles in the cavity.  As any delta particles with sufficient energy will exit the cavity 
without depositing the freed energy, the Spencer-Attix formulation uses the restricted stopping 
power, described in Chapter 2, to limit the interactions considered to those which deposit their 
energy within the cavity.  Any delta particles with energy above Δ are treated as part of the electron 
fluence spectrum [30].  With this adjustment, Equation 3.12 becomes: 
𝑠𝐴,𝐵 =
∫ 𝑑𝐸 (Φ𝐸)𝐴 ∗ (
𝐿Δ
𝜌 )
𝐴
𝐸𝑚𝑎𝑥
∆
+ (ΦE(Δ))A (
𝑆𝑐𝑜𝑙
𝜌
(Δ))
A
Δ
∫ 𝑑𝐸 (Φ𝐸)𝐵 ∗ (
𝐿Δ
𝜌 )
𝐵
𝐸𝑚𝑎𝑥
∆
+ (ΦE(Δ))B (
𝑆𝑐𝑜𝑙
𝜌
(Δ))
B
Δ
.               (3.13)          
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3.3. Dosimeters 
The application of cavity theory allows the use of dosimeters to rigorously measure dose 
to media.  By definition, a dosimeter is any device with a measurable quantity which correlates to 
a quantity of radiation [35].  This definition is as broad as it sounds, and many varieties of 
dosimeter exist.  Different types of dosimeter are suitable for different applications.  For example, 
calorimeters offer a direct measurement of the energy deposited, but are difficult to use.  As a 
result, they are limited to use in primary standards labs.  Less demanding devices, such as 
ionization chambers or diode detectors, are commonly used for clinical dosimetry of radiation 
beams. 
To ensure accuracy in the result, the measured signal Mraw must be corrected.  Corrections 
to the measured signal for environmental conditions, electron-ion recombination within the 
detector, and signal losses within the measurement apparatus exist for most detectors.  The exact 
corrections necessary depend on the type of detector and measurement.   
 Generally, the dose D to a point in the medium can be determined from the corrected 
detector response M and the absorbed dose to the detector dose ?̅?𝑑𝑒𝑡 via: 
𝐷 =  
𝑀
(
𝑀
?̅?𝑑𝑒𝑡
)
∗ 𝑠𝑚𝑒𝑑,𝑑𝑒𝑡                                               (3.14 )            
The ratio 
𝑀
?̅?𝑑𝑒𝑡
 is the detector response, which is determined by relation to a primary standard.  
Correction factors are applied to 𝑠𝑚𝑒𝑑,𝑑𝑒𝑡 to account for effects neglected in the ideal case (e.g. 
energy deposited by electrons generated within a Spencer-Attix cavity) [35].   
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3.3.1. Ionization Chambers 
Ionization chambers are a common form of dosimeter.  They consist of a gas filled cavity 
containing an anode and cathode.  This cavity is known as the active volume of the detector, and 
is the region in which energy deposition is measured.  Ionizing radiation produces electron-ion 
pairs in the gas, which are accelerated by the electric field between the electrodes. The charge 
collected by the electrodes is correlated to the dose.  Ionization chambers are very well established 
measuring devices, being the standard for clinical reference dosimetry in radiation oncology [39]. 
 
3.3.2. Diode Detectors 
The active volume of a diode detector is the depletion region of a silicon p-n junction.  An 
electric field is produced in this region by the buildup of excess electrons on one side and the 
absence of electrons on the other.  Any atomic electron freed from the silicon crystal in this region 
will be accelerated to one side by the electric field while the resulting “hole” will be filled by an 
electron from up-field, causing the hole to appear to move with the electric field.  The charge 
collected at the ends of the junction is correlated to dose in a similar manner to ionization 
chambers.  Though not used in reference dosimetry, diodes are known to have a good energy 
response and excellent spatial resolution, and remain useful for other clinical applications, 
particularly small field dosimetry [40]. 
 
3.4. Dosimetric Measurements 
 Dosimetric characterization focuses on particular features of the beam.  This focus defines 
the beam in terms of easily quantified features, ensuring the accuracy of comparisons without 
excessive complexity.  Percent-depth dose curves, dose profiles, and point dose measurements are 
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Figure 3.3. Detector setup and field size definitions.  Source-surface distance (SSD) and source-
axis distance (SAD) are shown.  Image from Almond et al. 1999 [34], used with permission. 
 
used to characterize radiation beams used in radiotherapy.   
The source used to generate the radiation beam will influence the measurements.  60Co 
sources are used as a reference for radiation dosimetry because they have a constant and universal 
photon energy.  Measurements of any other source (e.g. linac or synchrotron-generated beams) are 
referenced to 60Co for dose calculations [34]. 
To ensure consistency, the measurement medium must be positioned at a set distance from 
the source for all measurements.  This may be defined by the source-to-surface distance (SSD), 
the distance from the beam source to the medium surface, or the source-to-axis distance (SAD), 
the distance from the source to the dosimetric reference point.  These configurations are shown in 
Figure 3.3.  It is recommended that measurements of high energy photon beams be performed in 
water [34].  Water provides a dose buildup region which allows the detector to be repositioned 
freely, and its interactions with ionizing radiation are well known.  Furthermore, for medical 
Detector 
Detector 
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applications, humans are considered to be nearly water-equivalent, since soft tissue consists mainly 
of water and the differences are generally too small to be observed [35].  Low energy photon beams 
are instead characterized by air-kerma measurements, since water attenuates the beam by too great 
an extent for dose at depth to be an informative measure [41].  Two categories of clinical dosimetric 
measurements exist: reference dosimetry and relative dosimetry. 
 
3.4.1. Reference Dosimetry 
 Reference dosimetry serves to establish the baseline output of a radiation source.  It is 
performed at the time of commissioning, and updated periodically thereafter.  Reference dosimetry 
makes use of percent depth dose measurements and single point measurements to formally 
establish the output of a radiation beam and reference it to a national standard. 
 
3.4.1.1. Beam Quality 
Beam quality (Q) is a factor which depends on the energy spectrum of the beam, which 
serves to relate an MV photon beam to a 60Co source [34].  It is used to trace dosimetric 
measurements back to a national standard to ensure consistency in reported values.  The beam 
quality is defined using percent depth dose, described in Section 3.4.2.1.  The American 
Association of Physicists in Medicine (AAPM) recommend that the percentage of the maximum 
dose at 10 cm depth in water be used to specify beam quality.  An alternate formalism published 
by the International Atomic Energy Agency (IAEA) uses the tissue-phantom ratio, the ratio of 
doses at 20 cm and 10 cm depth, for the same purpose [42].  The two methods were shown to 
specify beam qualities which agree to within ±2% for high energy photon beams, so either 
formalism may be used in reference dosimetry [43]. 
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3.4.1.2. Point Dose 
 Point dose measurements record the energy absorbed by a region at a reference location.  
Point dose measurements are extremely important in radiation oncology, being crucial for 
treatment planning.    
Measurements of absolute point dose are necessary to quantify the output of the radiation 
beam.  Reference dosimetry is the procedure used to set the dose to a reference point.  The detector 
response must be converted to dose to water (𝐷𝑤
𝑄) via: 
𝐷𝑤
𝑄 = 𝑘𝑄𝑁𝐷,𝑤
𝐶𝑜60
𝑀,                                                     (3.15)           
where kQ is the quality conversion factor, which converts the detector calibration factor determined 
by calibration with a 60Co (𝑁𝐷,𝑤
𝐶𝑜60
) source to a value for the clinical beam [34].  With the dose to 
a reference point known, the beam’s relative dosimetric qualities can be extrapolated. 
 
3.4.2. Relative Dosimetry 
 Relative dosimetry is used to relate the dose delivered by a radiation beam for any setting 
back to the reference value determined by reference dosimetry.  It makes use of relative 
measurements to determine how variations in the beam definition affect the delivered dose. 
 
3.4.2.1. Percent Depth Dose 
Since interaction cross-sections are energy dependent, and particles lose energy as they travel 
through matter, radiation beams can be effectively characterized by how the dose changes along 
the central axis of the beam.  Percent depth dose (%DD) curves are a plot of dose as a function of 
depth normalized to dmax.  %DD for a 6 MV photon beam is shown in Figure 3.4. 
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Figure 3.4. A percent depth dose curve for a 6 MV photon beam.  %DD(dmax) and %DD(10) are 
labelled. 
 
The main features of interest in a percent depth dose are dmax and the percent dose at a 
depth of 10 cm (%DD(10)).  Recall from Section 3.1.4 that dmax is the location of true charged 
particle equilibrium.  As seen in Figure 3.4, relative dose increases with depth up to dmax, and 
decreases thereafter as more electrons deposit all of their energy and stop.  Obviously, the depth 
at which electrons can be freed, and the energy of the electrons, is proportional to the energy of 
the incident photons, making dmax a clear indicator of beam energy [35].   
%DD(x), the percentage of the peak dose delivered at depth x, is defined as: 
%𝐷𝐷(𝑥) =  
𝐷(𝑥)
𝐷(𝑑𝑚𝑎𝑥)
.                                          (3.16)           
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3.4.2.2. Dose Profiles 
Dose profiles are a plot of the relative dose as a function of axial position at a constant 
depth in the medium.  In the case of irregular dose distributions, such as the mini-beam collimated 
field, they are extremely useful for correlating the relative dose to position in the field.  Figure 3.5 
shows the dose profile of a 10 cm x 10 cm beam at 10 cm depth, with an SSD of 100 cm.  The 
width of the beam is defined at the Full Width – Half Maximum (FWHM), the width of the profile 
at a dose level of 50%. 
The central region of the field is where lateral charged particle equilibrium is observed.  
Due to this condition, dose is roughly constant across the central region.  The penumbra is the 
transition region where lateral charged particle equilibrium is lost due to the jaws occluding the 
field.  The standard penumbra definition is the region between two specified dose levels (e.g. 80% 
to 20%) [44].   The umbra is the region where the beam is entirely occluded by the jaws, with only 
a very few stray particles delivering a dose [3].  Note that the umbra spans a much wider area than 
the rest of the profile. 
 
3.4.2.3. Point Dose and Relative Output Factors 
 In addition to the obvious utility of checking the dose delivered to a reference point, point 
dose measurements are also used to relate the dose delivered using different field sizes.  This 
comparison uses relative output factors (OF), the ratio of point dose in the clinical field of interest 
(fclin) to the point dose in a reference field (fref).  Relative output factors are defined as: 
𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑤 = 
𝐷𝑓𝑐𝑙𝑖𝑛
𝑤
𝐷𝑓𝑟𝑒𝑓
𝑤                                                      (3.17)           
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Figure 3.5. A dose profile for a 6 MV photon beam with a field size of 10 cm x 10 cm at 10 cm 
depth.  The dose is normalized to the central axis value.  The central region (1), penumbra (2), 
umbra (3), and FWHM are labelled. 
 
 By determining the relative output factors for a range of fields, the changes in delivered 
dose due to change in field can be characterized.  In conjunction with characterization of how the 
beam 
energy changes with depth via the percent depth dose, the dose delivered by the beam can be 
predicted for a range of clinical fields. 
 
3.5. Uncertainty Analysis 
 Obviously, no measurement can be perfect.  All measured values possess an uncertainty, 
representing the range of values the quantity could reasonably be said to equal.  Quantifying the 
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uncertainty serves to quantify the precision of the measured values and allows one to see whether 
or not multiple measured values are in agreement.   
 Uncertainties are divided into two categories: Type A and Type B.  Type A uncertainty 
accounts for random variation between measurements.  It is estimated from the standard deviation 
of repeated experimental trials.  Given a series of N independent experimental measurements of a 
quantity x, such as point dose or %DD(10), the mean value: 
?̅? =  
∑ 𝑥𝑖
𝑁
,                                                          (3.18 )          
is taken to be the measured result and the 1σ Type A uncertainty (uA) would be calculated from 
the variance (𝜎) such that: 
𝑢𝐴 = 
𝜎(𝑥)
√𝑁
= √
∑(𝑥𝑖 − ?̅?)2
𝑁(𝑁 − 1)
.                                          (3.19)           
Since 1σ uncertainty reflects a confidence interval of only 68%, this estimate may be multiplied 
by a “coverage factor” corresponding to higher sigma confidence intervals.  2σ (95%) and 3σ 
(99.7%) are the most commonly used intervals [45].  Type B uncertainties account for any external 
influence that cannot be identified via statistical analysis.  There are no established rules for 
estimating Type B uncertainty, but steps can be taken in the experimental structure to mitigate the 
effects.  Uncertainties, being standard deviations, must be combined as the sum of the variance of 
each quantity [45]. 
 
 Direct measurements of dose are not always feasible.  For example, time or material 
constraints may prevent repeated experimental measurements to determine how to deliver the 
selected dose, or the region of interest may be inaccessible to detectors, as with a live patient.  For 
such situations, simulations of the beam may be used.  
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CHAPTER 4 
MONTE CARLO SIMULATION TECHNIQUES 
 
Simulations are a valuable tool for the study of radiation.  Properly validated simulations 
allow convenient analysis of beams, accelerators, and attachments.  In medical physics, radiation 
beams are often simulated using Monte Carlo particle transport algorithms.  Monte Carlo 
simulations sample probability distributions for interactions to model the path of particles in a 
medium.  A representation of the radiation beam can be constructed by simulating the paths of 
many particles.   
This chapter will provide a brief history of the Monte Carlo method and introduce the 
mechanics of Monte Carlo particle transport.  Variance reduction techniques will be presented 
before closing with an introduction to EGSnrc3, the Monte Carlo user code employed in this study. 
 
4.1. History of the Monte Carlo Method 
The idea of using repeated randomized tests to calculate a quantity of interest dates back to 1777, 
when Georges-Louis Leclerc proposed a method of calculating the probability (Pr) that a needle 
would overlap a line on a ruled sheet of paper when tossed onto it by recording the result of 
repeated tosses.  A century later, Pierre-Simon Laplace noted that Leclerc’s result was equivalent 
to: 
                                                          
3 EGSnrc is a development of the Electron Gamma Shower 4 [46] Monte Carlo software package developed at the 
Stanford Linear Accelerator Center. 
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Pr(𝑐𝑟𝑜𝑠𝑠𝑖𝑛𝑔) =
2𝑙
𝜋𝑑
,                                                (4.1)           
where l is the length of the needle and d is the line spacing.  Laplace proposed that this result could 
be rearranged to calculate π via repeated tosses of the needle [47].  The accuracy of this estimation 
increases with the number of trials, as the fraction of tosses which cross a line converges to the 
actual probability.  However, calculating π in this way is inefficient and tedious.   
 The use of results randomly sampled from a probability distribution to simulate particle 
transport is credited to Stanislaw Ulam and John von Neumann, who expanded an insight of 
Ulam’s to model neutron transport in thermonuclear weapon designs.  The sampling method was 
used to ease the theoretical calculations involved by analyzing probable outcomes from a sample 
of possibilities rather than performing the necessary matrix operations to rigorously track particle 
outcomes through a medium.  In their 1949 paper, Ulam and Metropolis codified the evaluation of 
computationally difficult problems via the examination of many random trials, which coined the 
term “Monte Carlo method.”  This paper also advanced the idea of simulating particle transport 
via “chains of events,” which made computation feasible [48]. 
 
4.2. Theory of the Monte Carlo Method 
 The Monte Carlo method is sometimes called the “method of statistical trials,” since it is 
based on approximating quantities through repeated random events.  If the probability distribution 
used is accurate and the number of particles tracked is sufficient, the results will converge to the 
actual outcome. 
 In order to perform Monte Carlo calculations it is necessary to generate random numbers.  
Truly random numbers cannot be chosen by a computer, but routines called random number 
generators (RNG) can generate “pseudo-random” numbers that are nearly random for the purposes 
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of the simulation.  RNGs use an algorithm to produce a sequence of numbers which bear no 
apparent connection to one another.  This is generally accomplished by manipulating the bits of a 
seed number to produce a new number.  Any repeated call of an RNG will eventually restart the 
sequence, which is the key difference between pseudo-random and truly random numbers.  An 
RNG suitable for Monte Carlo calculation must output a sequence of numbers which is uniformly 
distributed, does not repeat within the duration of a simulation, and cannot be statistically 
correlated [49]. 
 For many applications where the Monte Carlo method is advantageous, evenly distributed 
random numbers are not sufficient.  Monte Carlo algorithms must use random numbers which 
accurately reflect the probability distribution of each result.  This is accomplished by defining a 
probability density function 𝑝(𝑥) such that the probability of a result with a value between a and 
b is: 
Pr(𝑎 < 𝑥 < 𝑏) = ∫ 𝑑𝑥 𝑝(𝑥)
𝑏
𝑎
,                                     (4.2)           
which reflects the probability of each interaction or result.  Using such a distribution to weight an 
RNG output r uses the cumulative probability function: 
𝐺(𝑥) = Pr(𝑎 < 𝑥) = ∫ 𝑑𝑥′ 𝑝(𝑥′)
𝑥
𝑎
,                                 (4.3)           
where a is chosen such that Pr(𝑎) = 0 [50].  By transposing 𝐺(𝑥), the weighted random output R 
is found such that: 
𝑅 = 𝐺−1(𝑟)                                                         (4.4)           
where R is distributed according to 𝑝(𝑥). 
If 𝐺−1 cannot be determined, the rejection method must be used instead.  The rejection 
method involves selecting a transposable comparison function 𝑔′ such that 𝑔′(𝑥) > 𝑝(𝑥) to be 
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used for sampling.  If a random number between 0 and 𝑔′(𝑅) is less than 𝑝(𝑅), 𝑅 is accepted as 
following 𝑝(𝑥), otherwise new numbers are selected [46]. 
As the results of a Monte Carlo simulation are based on N repeated measurements of a 
quantity, the uncertainty in the quantity of interest is given by: 
𝑢𝑀𝐶 = 
𝜎
√𝑁
,                                                            (4.5)           
just as described for repeated measurements in Chapter 3 [49].   
 
4.3. Monte Carlo Particle Transport 
 Due to the many complex dependencies involved in modelling particle interactions, 
accurate analytic solutions are often difficult to obtain.  However, the Monte Carlo method 
simulates particle transport as a series of interactions.  The interaction and result at each event can 
be determined by sampling the probability distributions for the interaction cross sections and 
resultant particle energies and trajectories.  By using the result of each interaction to set the initial 
conditions of the next, the state of the particle and the energy it deposits as it passes through the 
medium are recorded.  A full particle path simulated in this manner is called a “history.”  By 
simulating the histories of many particles, a representation of a radiation beam can be constructed.  
Due to the random nature of the calculations, no two simulations will produce an identical history, 
but the outcomes of multiple simulations of sufficiently numerous histories will produce overall 
results that are equivalent within the simulated uncertainties.  
 To define 𝑝(𝑥) for the interactions, the medium must be described.  Monte Carlo programs 
make use of files containing geometric and cross-sectional data to model the simulated media.  In 
some implementations, such as the EGSnrc package used in this work, the simulated media are 
defined by groups of three-dimensional volume elements called “voxels.”  Each voxel is composed 
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of a single substance (e.g. air, water, bone).  Monte Carlo simulations transport particles through 
arrangements of voxels corresponding to the structure of the radiation source and irradiated media.   
At each simulated step the particle undergoes an interaction.  The standard process for 
simulating a particle interaction is as follows: 
 Determine the location of the interaction from the result of the last step. 
 Select the interaction by sampling the cross-sectional data. 
 Simulate the interaction to determine the resulting energy and trajectory of the particle. 
 Update the “stack”, the list of particles queued for simulation and begin the next iteration. 
This process is repeated for all interactions experienced by each particle in the simulation.  
Most Monte Carlo codes follow particles via a “last-in, first-out” scheme, where secondary 
particles created by an interaction are followed until they fully attenuate before the transport of the 
initial particle resumes [51].  The particulars of each step depend on the particle being transported. 
 
4.3.1. Electron Transport 
As described in Chapter 2, electrons experience constant Coulomb interactions rather than 
discrete interactions in the medium.  It was not until Martin Berger’s condensed history method 
came into use that electron transport could be easily simulated [52].  The condensed history method 
treats all of the electron interactions within a medium and energy-dependent distance as a single 
hard interaction.  In the simulation, the division between soft and hard collisions is set by an energy 
threshold for freed electrons and Bremsstrahlung photons.  Berger described two methods for 
condensed histories: Class I, which groups soft and hard collisions, and Class II, which groups 
only the soft collisions and explicitly simulates hard collisions [51].  An example electron path 
and the associated condensed history path are depicted in Figure 4.1. 
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Figure 4.1.  Electron path and an associated condensed history electron transport path.  
Secondary particle tracks are not shown. 
 
The implementation of condensed histories used by the EGSnrc user code is summarized 
here as an example of the process.  The electron energy at the time of the next high energy 
interaction is sampled from the atomic cross sections for collisional and radiative interactions.  The 
electron energy, position, and trajectory which most closely agree with the electron transport 
parameters are determined based on the sampled energy.  The interaction type is sampled from the 
relative interaction cross sections and simulated.  Following the interaction the resulting particles 
and associated energies and trajectories are logged, and the process repeats for the next step [53]. 
The continuous slowing down approximation (CSDA) is used to determine the electron 
path lengths and describe the soft collisions which are grouped in the condensed history.  CSDA 
assumes that the electron loses energy in a steady and predictable manner, and ignores the 
deflections caused by soft interactions.  It determines the path length from the stopping power of 
the medium for the electron energy.  As a result, the spatial separation between the simulated hard 
collisions decreases as the electron loses energy [54]. 
Real Path 
Simulated Path 
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4.3.2. Photon Transport 
 As described in Chapter 2, photons experience discrete interactions with the medium.  
Thus, interactions of indirectly ionizing radiation translate naturally to the process described in 
Section 4.2.2.  Each interaction can be treated separately, being separated in space.  The distance 
d between two photon interactions is randomly determined from the linear attenuation coefficient 
for the medium via: 
𝑑 = −
ln(1 − 𝑟)
𝜇
.                                                     (4.6)           
 Upon reaching the interaction site, the photon interaction is determined by sampling the 
relative interaction cross sections for the photon energy.  The results of the interaction are 
calculated in a similar fashion to electron interactions.  Any secondary particles are added to the 
stack for future transport [51]. 
 The EGSnrc process for simulating photon interactions is again used as an example.  The 
interaction type, atom, and electron shell are selected by sampling the interaction cross sections.  
Next, the outcome of the interaction is selected.  Each interaction requires a different process.  If 
a photoelectric interaction is simulated, the resultant kinetic energy of the electron is known from 
the target shell’s binding energy, and the electron emission angle is sampled from the angular 
distribution.  If a Rayleigh interaction is simulated, the only quantity of interest is the emission 
angle, which is found by sampling the emission angle distribution.  If a Compton interaction is 
simulated, the scattering angle of the photon is sampled from the scattering angle distribution, and 
used to calculate the electron recoil angle and the associated energy of each particle.  If a pair 
production interaction is simulated, the emission angles are calculated by sampling the angular 
distributions, and the particle energies are calculated by sampling the energy split [53]. 
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4.4. Variance Reduction Techniques 
 As described in Equation 4.5, the uncertainty in the result of a Monte Carlo simulation 
improves as the number of trials increases.  In order to evaluate the precision of the simulation, a 
method of determining the uncertainty is necessary. 
The uncertainty in the simulation results can be decreased by using a greater number of 
histories.  However, since the uncertainty is inversely proportional to the square root of the number 
of histories, the duration of the simulation increases quadratically with the precision.  This is 
quantified by the efficiency (𝜖) such that: 
𝜖 =
1
|𝑢𝑀𝐶|2𝑇
 ,                                                          (4.7)           
where T is the time required to simulate the number of histories.   
 Variance reduction techniques (VRT) are modifications to the Monte Carlo algorithms 
which improve the efficiency of the simulation by reducing the uncertainty without increasing the 
number of histories.  VRTs make the regular use of Monte Carlo simulation techniques much more 
feasible by reducing the time required to compute a result with sufficiently low uncertainty.  By 
the formal definition, a VRT will obtain an equivalent result for a simulation with a fixed 
uncertainty.  However, approximate techniques which can change the result are often referred to 
as VRTs as well, and care must be taken to ensure that the techniques used to not influence the 
result [55]. 
 
4.4.1. Particle Splitting 
Particle splitting involves replacing a secondary particle that would ordinarily be emitted 
by an interaction with multiple unique secondary particles.  Each of the split particles is treated as 
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having an equal fraction of the total statistical weight of the initial particle [53].  Particle splitting 
is commonly applied to Bremsstrahlung emission, but the principle can be applied to any particle 
generated by an interaction (e.g. Compton emission or annihilation photons). 
Particle splitting improves the uncertainty of a simulation by increasing the number of 
particles which pass through the medium without requiring extra histories to generate them.  
However, excessive splitting can lead to a large number of statistically insignificant particles being 
simulated.  If many split particles are generated alongside non-split particles, the results of the 
“fat” (high statistical weight) particles will tend to suppress the results of the split particles.  This 
will lead to an increase in simulation time without significant improvements in the uncertainty.  
Careful selection of the splitting number is required to maximize simulation efficiency [55]. 
 
4.4.2. Russian Roulette 
 Russian roulette involves randomly discarding particles at the time of their creation.  
Particles are selected for elimination by comparing a random number between zero and one to the 
survival threshold, the fraction of particles which are kept, for a given particle type.  The statistical 
weight of all remaining particles is raised in response to discarded particles [55]. 
 Russian roulette serves to reduce the time for the simulation by reducing the computation 
time necessary to achieve the desired uncertainty.  It tends to have the opposite effect to particle 
splitting, in that fat particles can be produced, causing some outcomes to be afforded greater 
statistical weight than would be accurate.  The survival threshold must be set appropriately to 
balance this possibility.  
 Particle splitting and Russian roulette are often used in conjunction to balance the 
drawbacks of each method.  Particle splitting is applied to the bremsstrahlung photons to rapidly 
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produce a full photon spectrum while the delta particles are subjected to Russian roulette to save 
time on electron transport.  In this case, the recommended practice is to set the survival threshold 
to be the reciprocal of the splitting number [56].   
 
4.4.3. Range Rejection 
 Range rejection involves terminating the transport of an electron and forcing it to deposit 
all remaining energy in the current dose scoring region if is not likely to leave the current region 
of interest.  Electrons are selected by comparing the energy of the electron to a threshold called 
the cut-off energy, and terminating it if it is below the cut-off.  The cut-off energy must be selected 
according to the average range of electrons in the medium, such that the majority of particles 
eliminated would have deposited their energy in the voxel.  Failure to select an appropriate cut-off 
energy will introduce error into the simulation.  Some Monte Carlo simulation programs, such as 
EGSnrc, are coded to set the threshold for each region to reduce the potential for error [56].  Given 
a properly selected threshold, range rejection reduces the simulation time without affecting the 
accuracy of the result. 
 
4.4.4. Photon Forcing 
 Photon forcing involves triggering an interaction within a given component module, for all 
photons which pass through it.  The result of the forced interaction is a scattered photon with 
statistical weight proportional to the probability of an unforced interaction, and an unscattered 
photon with the remaining statistical weight [56].  It is primarily used when the simulation is 
intended to study the effects of a small component module, which may not be subject to a large 
number of unforced interactions.  However, the process of transporting the photon to the 
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interaction point may increase the simulation time, especially if the component is large enough to 
allow multiple interactions [55].  
 
4.4.5. Cross Section Enhancement 
 Cross section enhancement is used to increase Bremsstrahlung production by multiplying 
the probability of radiative electron interactions by an enhancement factor.  It allows more rapid 
generation of photon fluence useful for further simulation.  The statistical weight of each photon 
in decreased proportionally to the enhancement factor [55].  Cross section enhancement is best 
used for low energy charged particles, which produce so few photons that particle splitting does 
not improve the simulation time, or in conjunction with particle splitting to produce a large number 
of photons in few histories [56].   
 
4.5. EGSnrc 
 EGSnrc is a Monte Carlo particle transport code developed by the National Research 
Council of Canada. EGSnrc includes several refinements to the physics models used by EGS4, 
and is periodically updated with the latest developments [53].  EGSnrc consists of several 
applications which address different aspects of the simulation and analysis of radiation transport 
as applies to dosimetry. 
 
4.5.1. BEAMnrc 
 BEAMnrc [57] is a software tool used to simulate radiation beam sources (e.g. a medical 
linear accelerator).  BEAMnrc simulates a radiation source via an accelerator file, consisting of a 
series of component modules ordered by their position along the main axis of the accelerator.  One 
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BEAMnrc output is a phase space file, which contains a record of particle position, energy, and 
trajectory at a plane.  A phase space file can be used in further simulations or used to analyze the 
output of a source.   
BEAMnrc inputs specify the accelerator file, the simulation settings (e.g. number of 
histories, desired outputs), the particle source, the transport parameters (e.g. maximum step size, 
VRT settings), and the location and composition of the component modules.  The particle source 
may be a Gaussian or rectangular particle source, a phase space file, or even another BEAMnrc 
simulation to generate a particle for each new history.  The source is defined in terms of particle 
type, particle energy, position, and orientation.  BEAMnrc outputs a phase space file for a specified 
plane or planes normal to the main axis, and a data file contacting the statistics on the simulation 
as a whole [56]. 
 
4.5.2. DOSXYZnrc and DOSRZnrc 
 DOSXYZnrc and DOSRZnrc are software tools used to calculate absorbed dose in media 
defined using Cartesian and cylindrical coordinates respectively.  The volumes of interest are 
defined by ranges of voxels located relative to a reference point.  Each voxel both defines the 
medium and serves as a dose scoring region. 
 DOSXYZnrc and DOSRZnrc inputs define the beam and transport geometry, set the 
simulation parameters, and specify the output format.  Like BEAMnrc, they can use particle 
sources, phase spaces, or BEAMnrc simulations as sources.  The two codes produce different 
outputs.  DOSXYZnrc produces a “3ddose" file, which stores the dose to each scoring region in 
the voxel array and the associated uncertainty [58].  This can be analyzed and represented via 
profiles and percent depth dose curves.  DOSRZnrc records the dose absorbed by specified scoring 
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region or regions.  DOSRZnrc can also record other aspects of energy deposition (e.g. dose due to 
scattered particles, kerma) for analysis [59].   
  
 Monte Carlo simulations are a powerful tool in medical physics research.  Simulations can 
be used to easily test the effects of variation in the experimental parameters.  The ability to 
precisely alter and control parameters is invaluable.   However, no one tool can accomplish every 
task.  The outcomes of Monte Carlo simulations, especially those of novel delivery methods or 
accessories, must be validated against experimental data.  
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CHAPTER 5 
COLLIMATOR TRANSFERABILITY:  
DOSIMETRIC CHARACTERIZATION 
  
A design requirement of the mini-beam collimator was that it be easily implemented across 
multiple medical linear accelerators.  To verify that this condition is met, dosimetric 
characterization measurements of the mini-beam collimated field on multiple linacs was carried 
out.  The experimental measurements were divided into two parts.  One consisted of the spatially-
dependent measurements of the open and mini-beam collimated field.  These measurements 
included dose profiles and percent depth dose curves which were used to characterize the dose 
distribution and beam quality of the open and mini-beam collimated fields.  The other part 
consisted of the central axis point dose measurements of the collimated and open fields.  These 
measurements were used to calculate the relative output factors of the open and mini-beam 
collimated fields for each linear accelerator. 
This chapter will first give an overview of the initial dosimetric characterization 
measurements, including an overview of the setup and use of the mini-beam collimator and a 
summary of the quantities of interest.  Next, the experimental tools used in performing the 
measurements will be introduced.  The method by which the measurements were taken will be 
explained.  Finally, the results of the measurements will be presented and a discussion of the 
implications of these results presented. 
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5.1. The Mini-Beam Collimator  
 The dosimetric transferability of the mini-beam collimator was the goal of this study.  
However, the mini-beam collimator produces a mini-beam array, which exhibits significant 
changes in dose over very small spatial displacements.  Certain factors must be considered in the 
characterization of such a field that do not arise in a conventional field.  An overview of the mini-
beam collimator and the dosimetric framework necessary to characterize the beam is provided to 
place the measurements in context. 
 
5.1.1. Design 
 The collimator uses an array of tungsten blades 100 mm in depth and 0.6 mm wide mounted 
in an aluminum frame, which produces alternating high and low dose regions, as shown in Figure 
5.1.  The blades are arranged parallel to the nominal beam divergence angle, to ensure that the 
dose at each peak remains constant across the field.  The collimator assembly’s aperture is 4.2 cm 
x 4.2 cm, which allows for a mini-beam array for any field up to 5 cm x 5 cm projected at isocenter.  
The collimator assembly is mounted in a standard Varian accessory mount for attachment to the 
accelerator head.  The collimator mounting includes angular and lateral position adjustments.  The 
lateral position control has a precision of 1.0 micrometer.   
The mini-beam collimator divides the field by occluding regular sections with the tungsten 
blades.  The spaces between the blades, called “septa,” allow the beam to pass uninterrupted, 
producing the mini-beam array.  The blade spacing was specified to produce mini-beams with a 
width of 1 mm at isocenter [23].   
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Figure 5.1. Simulated dose profile of a mini-beam array at 10 cm depth in water. 
 
The collimator is shown in Figure 5.2.  The mini-beam collimator fits into the linear 
accelerator accessory mount below the jaws and multi-leaf collimators (MLC).  Thus, the only 
change between generation of a mini-beam collimated field and an open field is the presence or 
absence of the mini-beam collimator.    
 
5.1.2. Dosimetric Framework 
Relative output factors (𝑂𝐹𝑓
𝑤) and collimator factors (𝐶𝐹𝑓
𝑤) were obtained for the open 
fields (𝑓𝑐𝑙𝑖𝑛) and mini-beam collimated fields (𝑓𝑚𝑖𝑛𝑖), respectively.  These values were linked by 
a dosimetric framework developed during the commissioning of the mini beam collimator [23].  
As described in Equation 3.17, relative output factors are ratios of doses to water (𝐷𝑓
𝑤) used to 
characterize a field of interest (𝑓𝑐𝑙𝑖𝑛),  relative to a reference field (𝑓𝑟𝑒𝑓), such that: 
54 
 
 
Figure 5.2.  The mini-beam collimator mounted in the accessory mount of a Varian iX linear 
accelerator.  The yellow arrows indicate the collimator inclination adjustment screws, the blue 
arrows indicate the lateral adjustment micrometers, and the green arrow indicates the digital 
micrometer used to display lateral position [23]. 
 
𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑤 = 
𝐷𝑓𝑐𝑙𝑖𝑛
𝑤
𝐷𝑓𝑟𝑒𝑓
𝑤 .                                                       (5.1)           
When using the mini-beam collimator, the mini-beam relative output factor is defined as 
the product of the open field relative output factor (𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑤 ) and the collimator factor, such that: 
𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 = 𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑤 ∗ 𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 .                                         (5.2)            
It follows that the collimator factor, which accounts for the effect of the mini-beam 
collimator can be determined by the ratio of point doses along the central axis in the mini-beam 
collimated field to that in the open field, as depicted in Figure 5.3, such that: 
𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 =
𝐷𝑓𝑚𝑖𝑛𝑖
𝑤
𝐷𝑓𝑐𝑙𝑖𝑛
𝑤 .                                                    (5.3)           
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Figure 5.3. Experimental setups for collimator factor measurement.  (a) shows the detector in water 
under an open field.  (b) shows the detector in water with the mini-beam collimator in place.  The 
detector position and field size remain unchanged between the two setups. 
 
However, dose-to-water cannot be measured directly, and the calculation of a dose ratio 
based on measurement must account for the relative stopping powers and mass attenuation 
coefficients of the detector relative to water, as described in Equations 3.11 and 3.13 [60].  These 
coefficients are dependent on the field sizes being measured [61].  Therefore, measured collimator 
factor is more appropriately defined as: 
𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 =
𝐷𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡
𝐷𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 ,                                                     (5.4)           
and: 
𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 = 𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 ∗ 𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 .                                          (5.5)           
where 𝐷𝑓
𝑑𝑒𝑡 is the dose to the detector active volume in the field of interest. 
In the case of this experimental setup, the stopping power ratio between water and the 
detector active volume is relatively insensitive to a change between 𝑓𝑐𝑙𝑖𝑛 and 𝑓𝑚𝑖𝑛𝑖 [23].  Therefore, 
it can be assumed that the change in 𝐷𝑓𝑖𝑒𝑙𝑑
𝑑𝑒𝑡  is due entirely to the change in electron fluence between 
(a) (b) 
Detector 
 
 
 
Collimator 
 
 
 
Water 
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fields, as described in Equation 3.11, and the relative dose can be considered equivalent to the ratio 
of detector signals (𝑀𝑓𝑖𝑒𝑙𝑑
𝑑𝑒𝑡 ) such that: 
𝐷𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡
𝐷𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 =
𝑀𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡
𝑀𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 ,                                                   (5.6)           
And, therefore, Equation 5.4 can be expressed as: 
𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 =
𝑀𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡
𝑀𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 .                                                   (5.7)           
The open field relative output factor can be simplified similarly, such that Equation 3.17 can be 
expressed as follows: 
𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 =
𝑀𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡
𝑀𝑓𝑟𝑒𝑓
𝑑𝑒𝑡 .                                                    (5.8)           
 
5.2. Experimental Apparatus 
Experimental measurements using the mini-beam collimated field on each of the three 
medical linear accelerators (linacs) were performed with two unshielded diode detectors in a water 
phantom.  The experimental apparatus is shown in Figure 5.4. 
 
5.2.1. Medical Linear Accelerators 
Three clinically beam matched medical linear accelerators were used in this study.  All 
three were Varian Clinac iX accelerators, designated Linacs 1 – 3 for the purposes of this study.  
The medical linear accelerators are located at the Saskatoon Cancer Center.  All measurements 
were performed at a nominal beam energy of 6 MV. 
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Figure 5.4. Linac 1 with the mini-beam collimator installed, the MP3 water phantom positioned, 
and the TANDEM electrometer unit connected to the detector.   
 
The Saskatoon Cancer Centre’s requirement for clinical beam matching is agreement to 
within less than half the threshold recommended by TG-142 [62].  As described in Chapter 3, the 
AAPM TG-51 code of practice for reference dosimetry is used to calibrate the linear accelerator  
outputs and ensure consistency [34]. 
 
5.2.2. Diode Detectors 
Two unshielded diode detectors were used for the characterization measurements.  Diodes 
were selected over ionization chambers due to their small active volume size, granting the greater 
spatial resolution necessary to properly resolve the mini-beams. The PTW4 60017 (PTWe) has a 
circular active volume with a manufacturer specified diameter of 1.2 mm and an effective depth 
                                                          
4 PTW - New York Corporation, Brooklyn, NY, United States - www.ptw.de 
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Figure 5.5. The measurement axes defined with respect to the mini-beam collimator blades. 
 
of 3 mm.  The Scanditronix5 stereotactic field diode (SFD) has a circular active volume with a 
manufacturer specified diameter 0.6 mm and effective depth of 0.06 mm.  The accumulated charge 
from these detectors was read using a PTW TANDEM electrometer.  It should be noted that 
clinical dosimetric characterization measurements are typically performed using an ion chamber.  
However, the intent of these measurements was to compare the results across multiple linacs, 
which requires only that the same detector used on all measurements being compared, permitting 
the use of the higher resolution diode detectors. 
 
5.2.3. Water Phantom 
A PTW MP3 water phantom was used for all measurements.  The phantom consists of a 
water tank containing arms for positioning the detector.  The phantom is able to position the 
detector within a 50 cm x 50 cm x 40 cm volume with a manufacturer quoted uncertainty of ± 0.01 
                                                          
5 IBA Dosimetry, Bartlett, TN - http://www.iba-dosimetry.com 
Crossplane Axis 
Inplane Axis 
Beam Central Axis 
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cm in three dimensions.  When describing measurements with the mini-beam collimator, the axis 
perpendicular to the mini-beams is the “crossplane” axis and the axis parallel to the mini-beams is 
the “inplane” axis.  The axes relative to the mini-beam collimator blades are shown in Figure 5.5.   
 
5.2.4. MEPHYSTO mc2  
The PTW MEPHYSTO mc2 software package was used to perform and process the water 
tank measurements.  The characterization measurements made use of the CenterCheck, tbaScan, 
DataAnalyze, and TanSoft applications executed within the MEPHYSTO interface. 
 CenterCheck was used to determine the center point and inclination of the field 
relative to the water tank by examination of profiles of a square field in both axes 
at two depths.   
 tbaScan was used to perform profile and percent depth dose measurements.  It is 
also capable of analysis of the measured profiles and percent depth dose curves 
(e.g. calculating field size and dmax).   
 DataAnalyze was used to analyze and format (e.g. normalize or smooth) the profiles 
and percent depth dose curves.  As well, it can add or average multiple profiles or 
percent depth dose curves. 
 TanSoft was used as the software interface with the TANDEM electrometer when 
performing point dose measurements.  Measurements were performed using the 
charge measurement node over a 20 second integration time.  The 
TanSoft/TANDEM reading has a stated reproducibility of ±0.5%. 
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5.3. Experimental Setup 
To ensure consistency in the measurements, a standard procedure for setup was established 
and followed.  The AAPM recommendations for reference dosimetry [34] and commissioning [62] 
of high energy photon beams were used to guide the measurement procedure in order to ensure 
consistency with established dosimetry practice.  The following procedure was used for all 
experimental measurements. 
 
5.3.1. Water Phantom Setup 
 The first step was to position the water phantom and set up the associated equipment.  With 
the linear accelerator gantry angle set to 0˚, the water tank was aligned with the linear accelerator 
field and levelled using the adjustable base.  All angles were verified by the use of a digital level 
with a precision of ±0.05o.  The detector and electrometers were connected to the phantom and the 
computer operating MEPHYSTO.  All electrometers were located at the end of the treatment couch 
opposite the beam to prevent contamination of the signal by the radiation.  After all electronics 
were connected, the water phantom was filled to an SSD of 100 cm, the standard distance for 
reference dosimetry [34, 42].  The detector and positioning mechanism were kept below the water 
surface to ensure that water displacement was accounted for in the SSD measurement.   
 
5.3.2. Detector Centering 
 MEPHYSTO uses a set center point as the origin when locating the detector.  The centering 
process matches this point to the physical center of the field at the water’s surface.  The diode 
center was set before any measurements were taken and whenever the detector position was 
adjusted. 
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The centering procedure for the mini-beam field was adopted from earlier dosimetry work 
involving very small photon fields [64].  The diode was located near the beam center by visual 
inspection of detector center and the linear accelerator beam crosshairs.  CenterCheck was used to 
center the diode in a 2 cm x 2 cm open field with scans at 5 cm and 15 cm depth.  This step 
localized the detector to better than 1 mm of the field center, and served to verify that the gantry 
and water tank were level.  After this, tbaScan was used to double check the diode position.  
Profiles in both axes were taken for 1 cm x 1 cm and 0.5 cm x 0.5 cm fields at a depth of 10 cm 
with a detector axial positional increment of 0.03 cm.  The tbaScan Analysis tool was used to 
determine the central axis offset (CAX) from the beam.  The center point was corrected by the 
measured CAX, until the calculated offset from the field center was below ±0.01 cm, the maximum 
resolution of the detector positioning, for both fields.  
 
5.3.3. Mini-Beam Collimator Centering 
Due to the small size of the mini-beams, and the collimator being an attachment to the 
linear accelerator that was removed and replaced between measurements, it was necessary to verify 
the position of the mini-beam collimator as well.  This procedure was developed in the initial 
commissioning study of the mini-beam collimator [23].  First, the collimator inclination was 
checked with the level to ensure that it was aligned with the field.  After this was verified, the 
crossplane dose profile was measured for a 4 cm x 4 cm field at a depth of 10 cm with a detector 
position increment of 0.02 cm, twice the uncertainty of the detector position.  This provided the 
highest resolution possible while minimizing overlap of the active volume between measurement 
points.  The detector alignment with the central mini-beam was verified by visual inspection of the 
profiles to ensure that the central peak was coincident with the detector center position.   
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Figure 5.6. An illustration of the effect of angular misalignment.  (a) collimator inclination and 
beam inclination in .  (b) collimator inclination out of alignment with the beam inclination,  
 
In the event that an offset was found, it was necessary to adjust the collimator position.  
When performing this adjustment, the lateral positioning micrometers on the collimator base were 
adjusted by the offset measured by tbaScan until the central mini-beam was aligned with the central 
axis of the open field.   
 
5.3.4. Mini-Beam Collimator Alignment 
The design process and initial characterization of the mini-beam collimator assumed that 
the collimator was perfectly aligned with the beam central axis.  As shown in Figure 5.6, 
misalignment results in an increase in effective blade width, with an accompanying reduction in 
the effective width of the air septa which define the mini-beams.  The blade width was one of the 
key parameters during the design process, which had a significant impact on the dose distribution 
[23].   
(a) (b) 
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During dosimetric characterization, it was observed that the beam alignment with respect 
to the accessory mount varies between accelerators by an amount sufficient to cause observable 
changes to the measured collimator factor.  In order to eliminate this variation between the 
accelerators, it was necessary to adjust the collimator inclination to match the inclination of the 
beam central axis.  The collimator alignment step was added to the established measurement 
procedure to account for the effect. 
When measuring the collimator factor over a range of collimator inclinations, the highest 
measured collimator factor corresponds with the inclination at which the collimator is aligned with 
the beam.  Therefore, the collimator could be aligned by finding the inclination at which the 
collimated field point dose peaked, as this point has the highest ratio of 𝑀𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡  to 𝑀𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡  (Equation 
5.7).  The alignment was carried out by seeking this point. 
The inclination of the collimator was set using the angular adjustment screws.  Due to the 
high precision necessary to consistently locate the collimator inclination aligned to the beam, the 
position was defined by the change in the micrometer reading, and the corresponding change in 
angle was calculated from the collimator position at the level of the micrometer.  To locate the 
point of maximum dose, TanSoft was used to perform point dose measurements in a 4 cm x 4 cm 
field at 10 cm depth.  At each collimator inclination, the detector was centered in the mini-beam 
by adjusting the detector position in 0.01 cm increments in the crossplane axis and performing 
repeated measurements of the point dose at each step.  The centered detector position was that 
which obtained the highest dose.  The centered detector doses were compared in order to identify 
the point of maximum dose.  The 0o inclination was defined as the aligned inclination for the linac. 
It was observed that the peak dose tended to remain constant within measurement 
uncertainty near the peak, meaning the optimal inclination could not be conclusively determined 
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by a single measurement.  While the variation in dose over this region was within clinical tolerance, 
the range was too wide to carry out repeatable measurements at non-zero inclinations.  A second 
check was used to set the zero point of the collimator inclination with sufficient precision.  First, 
the approximate center was located by finding the range of inclinations over which the point dose 
remained unchanged.  The center of this region was taken as a starting center position.  The 
location of the center point was refined by performing point dose measurements at some non-zero 
inclination on each side of the peak.  The ideal center position was taken to be the point equidistant 
from equal point doses.  This condition was met by adjusting the offset measurement to minimize 
the difference between the point doses at each inclination.  An offset of 0.075 mm (0.086o), the 
largest change in inclination used in characterization measurements, was used for centering. 
  
5.4. Measurement Procedure: Dose Profile and Percent Depth Dose 
The same nominal 6 MV photon beam was used for all profile and percent depth dose 
measurements.  While 10 cm x 10 cm fields are the accepted standard for reference dosimetry [34, 
42], the width of the collimator aperture precluded such a wide beam.  A 4 cm x 4 cm field was 
used for profile and %DD measurements, as the 4 cm field was selected as the largest field which 
would be necessary during the collimator design process and was used as a benchmark during the 
commissioning study.  To reduce the effects of a particular setup, all measurements were 
performed at least three times for independent setups and averaged to calculate the reported value 
and associated uncertainty.  These measurements were taken with the SFD diode detector in the 
horizontal orientation.  This served to ensure that the active volume was wholly within the central 
mini-beams for %DD measurements and maximized the crossplane positional resolution in the 
dose profile measurements [65], as shown in Figure 5.7.   
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Figure 5.7. Diode detector structure and orientation.  Orientations 1 and 2 were used in this 
study, according to the needs of the measurement.  The same orientation was used for all 
measurements of a given type. Image from Beddar et al. 1994 [65], used with permission. 
 
5.4.1. Percent Depth Dose Measurement 
An important feature of the collimator which required verification was that the mini-beams 
are of equal beam quality to the open field.  This condition was tested via %DD measurements.  
%DD were taken along the beam central axis at increments of 0.1 cm from 0 cm to 2 cm depth, 
0.25 cm steps from 2 cm to 6 cm depth, and 0.5 cm from 6 cm to 25 cm depth.  %DD were 
measured for both collimated fields and open fields on each linear accelerator. 
 
5.4.2. Profile Measurement 
Dose profile measurements were taken along the central crossplane axis at increments of 
0.2 mm at the reference depth in water of 10 cm.  This fine increment was selected to properly 
resolve the mini-beams while ensuring that the separation between each measurement point was 
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greater than the positional uncertainty offered by the water tank.  For consistency, this resolution 
was also used for the open field measurements.  Dose profiles were obtained for both mini-beam 
collimated fields and open fields on each linear accelerator.  The mini-beam collimated profiles 
can be compared using the peak-to-valley dose ratio (PVDR).  The PVDR was calculated as the 
ratio of the average of the peak doses to the average of the valley doses such that: 
𝑃𝑉𝐷𝑅 =
𝐷𝑝𝑒𝑎𝑘
𝑎𝑣𝑔
𝐷𝑣𝑎𝑙𝑙𝑒𝑦
𝑎𝑣𝑔 .                                                       (5.9)           
Only the peaks and valleys within the central region of the beam are included when calculating the 
average values. 
 
5.4.3. Data Collation 
DataAnalyze was used to amalgamate the profile and percent depth dose measurements 
from multiple sessions.  The “Average” function was used to combine multiple measurements into 
a single result for each linac.  A minimum of three profiles or percent depth dose measurements 
were used to construct each averaged data set.  The “Smooth” function was used once on percent 
depth dose and open field profiles to eliminate any remaining noise in the averaged data set.  The 
profiles for the mini-beam collimated field could not be smoothed, as the smoothing algorithm 
removed the peaks and valleys which distinguish the mini-beam array. 
 
5.5. Measurement Procedure: Output Factors 
Point dose measurements were taken for the mini-beam collimated and open fields for field 
sizes of 2 cm x 2 cm, 3 cm x 3 cm, 4 cm x 4 cm, and 5 cm x 5 cm.  The measurement point was at 
10 cm depth in water and centered in the field.  To reduce the effects of a particular setup, all 
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measurements were performed at least three times for independent experimental setups and 
averaged to calculate the reported value and associated uncertainty.   
All point dose measurements for each field were performed for both detectors.  The 
detectors were used in the vertical orientation for point dose measurements.  In each measurement 
session, the measurements were first performed for all four collimated fields then for all four open 
fields to ensure that the collimator position was constant for all fields.  Each point dose reading 
was performed five times and the average of the values was taken.  These averages were taken to 
be the field point dose for that measurement session.   
The open field relative output factor was calculated from the ratio of point dose in the open 
field of interest relative to the point dose in the 5 cm x 5 cm field for the 2 cm x 2 cm, 3 cm x 3 
cm, and 4 cm x 4 cm fields, as described in Equation 5.8.  The 5 cm x 5 cm field was selected as 
the reference field [60]. 
 Measured collimator factors for each session were calculated from the ratio of the 
collimated field point dose to the open field point doses for the 2 cm x 2 cm, 3 cm x 3 cm, 4 cm x 
4 cm, and 5 cm x 5 cm fields, as described in Equation 5.4.  The mini-beam relative output factors 
were calculated by taking the product of the open-field relative output factors and the measured 
collimator factor, as described in Equation 5.5. 
 
5.5.1. Effects of Collimator Inclination on Collimator Factor 
 In order to characterize the relationship between collimator factor and collimator 
inclination with respect to the beam central axis, point dose measurements were performed for 
four collimator inclinations.  Both the PTWe and SFD detectors were used in the vertical 
orientation. 
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 Point dose measurements in the mini-beam collimated field and open field were taken at 
collimator positions of 0.000, ±0.025, ±0.050, and ±0.075 mm offset from the baseline position 
described in Section 5.3.3 and 5.3.4 (corresponding to changes in inclination of 0.00, ±0.03, ±0.06, 
and ±0.09o, respectively) for 2 cm x 2 cm, 3 cm x 3 cm, 4 cm x 4 cm, and 5 cm x 5 cm.  The 
measurements at the three non-zero inclinations were performed at the given offset in both 
directions from the 0.0o collimator inclination.   The collimator factor obtained for the collimator 
inclination of 0o was taken as the optimized collimator factor. 
 
5.5.2. Uncertainty in Measurements 
The uncertainty in the average measured value of N experimental setups was determined 
as described in Chapter 3, such that: 
𝑢𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 = 
2𝜎(𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 )
√𝑁
                                               (5.10)           
The uncertainty in the relative output factor was obtained in the same way.  When calculating the 
relative output factor as described in Equation 5.5, the uncertainties are added in quadrature, such 
that: 
𝑢𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 = √(𝑢𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 )
2
+ (𝑢𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 )
2
.                              (5.11)           
 
5.6. Experimental Results 
Measurements of the open field and mini-beam collimated field were used to 
dosimetrically characterize the mini-beam collimator on each medical linear accelerators.    
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 Linac 1 Linac 2 Linac 3 Mean 
%DD(10 cm) (%) 61.75 ± 0.21 61.83 ± 0.28 62.15 ± 0.64 61.84 ± 0.24  
dmax (cm) 15.99 ± 0.11 16.00 ± 0.68 16.10 ± 0.06 16.06 ± 0.07 
Field Size (cm) 4.40 ± 0.02 4.39 ± 0.02 4.40 ± 0.03 4.40 ± 0.01 
Beam Symmetry (%) 0.29 ± 0.01 0.43 ± 0.08 0.39 ± 0.02 0.33 ± 0.08 
 
Table 5.1.  Metrics of the open field and the associated uncertainty across the three linear 
accelerators.  The mean value and measurement uncertainty for each quantity are also given. 
 
5.6.1. Open Field Measurements 
 Table 5.1 summarizes the main features of the open field on the three linear accelerators.  
The %DD(10 cm) and dmax were obtained from the percent depth dose curves, and the field size 
and beam symmetry were obtained from the dose profiles.  The %DD, dmax, and field size at 10 
cm depth were compared to the mean value to quantify the dosimetric variation across linacs.   
The SCC requirement for clinical beam matching is agreement to within half the threshold 
recommended by TG-142 [62].  In the context of these measurements, the condition is satisfied by  
the %DD(10), dmax, and field size all showing agreement back to the baseline value within ±0.5%, 
and the beam symmetry being within ±0.5% of zero.  
Table 5.2 states the open field relative output factors calculated for each linear accelerator.  
The open field dose measurements for each field obtained by each detector were used to calculate 
these values for comparison.  All values were found to agree within ±0.5% of the mean, meeting 
the threshold for clinical beam matching. 
 
5.6.2. Mini-Beam Collimated Percent Depth Dose and Dose Profiles 
Measurements of percent-depth dose curves and dose profiles were performed before the 
effect of changes in the collimator inclination angle was quantified.  These results serve to 
demonstrate the effect of collimator alignment. 
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Linac 1 Linac 2 Linac 3 
Field (cm2) PTWe  SFD PTWe SFD PTWe SFD 
4 x 4 
0.964 
± 0.001 
0.963 
± 0.001 
0.963 
± 0.001 
0.961 
± 0.001 
0.962 
± 0.001 
0.961 
± 0.001 
3 x 3 
0.924 
± 0.001 
0.919 
± 0.001 
0.923 
± 0.001 
0.918 
± 0.001 
0.923 
± 0.001 
0.919 
± 0.001 
2 x 2 
0.880 
± 0.001 
0.871 
± 0.001 
0.878 
± 0.001 
0.870 
± 0.001 
0.878 
± 0.001 
0.870 
± 0.001 
 
Table 5.2.  The measured open field relative output factors (relative to a 5 cm x 5 cm reference 
field) with the measurement uncertainty for each accelerator and diode detector. 
 
5.6.2.1. Percent Depth Dose 
  Figure 5.8 compares the percent depth dose for the collimated fields with the average open 
field percent depth dose.  Table 5.3 states the dmax and %DD(10).  Little deviation from the open 
field can be seen, with a nearly identical dmax and %DD(10).   All collimated field dmax differ from 
the averaged open field dmax by less than ±0.43%.  All three linacs differed from the mean mini- 
beam collimated field %DD(10) by ±0.6% or less, slightly in excess of the local standard of ±0.5%, 
but satisfying the TG-142 standard.  The averaged open field %DD(10) was consistent with this 
range.  This satisfies the clinically beam matched criterion and shows that beam quality of the 
mini-beam collimated fields is clinically equivalent to that of the open field.  However, the surface 
dose is slightly higher for the mini-beam collimated fields than for the open field.  This is indicative 
of electron contamination: low energy electrons freed from the mini-beam collimator by photon 
interactions influencing the energy spectrum [33]. 
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Figure 5.8.  %DD for the mini-beam collimated field on each linear accelerator.  Also shown is 
the average of the %DD for the open field, as calculated using the MEPHYSTO software. 
 
Linac %DD(10) dmax (mm) 
1 61.25 ± 0.18 16.10 ± 0.29 
2 61.93 ± 0.24 15.99 ± 0.36 
3 61.49 ± 0.17 16.00 ± 0.49 
Open 61.84 ± 0.24 16.06 ± 0.07 
 
Table 5.3. Beam quality specification for the collimated fields on each linear accelerator and the 
average of the open fields, all with the measurement uncertainty.   
 
5.6.2.2. Dose Profile 
Figure 5.9 shows the dose profiles of the mini-beam collimated field on each linear 
accelerator, normalized to the central axis dose.  Also included is the average of the three open- 
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Figure 5.9.  Dose profiles (normalized to the central axis dose) at 10 cm depth for the mini-beam 
collimated field on each linear accelerator.  The average of the dose profiles at 10 cm depth for 
the open field, as calculated by MEPHYSTO, is also shown.   
 
Linac PVDR 
1 1.510 ± 0.003 
2 1.446 ± 0.003 
3 1.343 ± 0.003 
 
Table 5.4.  The calculated peak-to-valley dose ratio and uncertainty for each linear accelerator.   
 
field profiles.  The associated PVDR are shown in Table 5.4.  The overall spatial dose distribution 
is consistent across the linacs, and matches the footprint of the open field measurements.  However, 
the profiles disagree across linacs in two main regards. 
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The most interesting result shown in Figure 5.9 and Table 5.4 is the variation in PVDR.  
The lowest PVDR (Linac 3) and the highest PVDR (Linac 1) differ by 11.1%, having a maximum 
deviation from the mean PVDR of 6.3% in the case of Linac 3, exceeding the measurement 
uncertainty and beam matching threshold.   
Note also that the peak doses are not perfectly consistent from peak to peak.  This is due to 
the limitations of the manufacturing process, since subtle irregularities in the blade spacing can 
cause an observable difference in the peak dose.  However, the relative dose of each peak is 
consistent across all medical linear accelerators (e.g. the peak immediately to the left of the central 
peak is lower than average for all three linacs).  While non-ideal from a dosimetric perspective, 
this variation remains within acceptable bounds, and proved useful to ensure that the collimator 
was always centered on the same peak. 
 
5.6.3. Collimator Factors 
Collimator factor measurements were performed on each linear accelerator.  Figure 5.10 
shows the measured collimator factors for each linac correlated with field side length.  The values 
are also stated in Table 5.5.  They show that the collimator factor decreases with increasing field 
side length.  The relationship between the two quantities is linear within the measurement 
uncertainty. 
Also evident in Figure 5.10 is the change in collimator factor across linacs, with deviation 
from the mean of up to 2.8% in the case of Linac 3.  This is well in excess of the measured 
uncertainty, and exceeds the threshold for beam matching.  This discrepancy is observed for both 
detectors, which show the same ordering of collimator factors.  Also note that the collimator factors 
measured by the two detectors differ.  This is a feature of the detectors.  The nominal diameter of 
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Figure 5.10.  Measured collimator factors for each diode detector.   
 
the PTWe active volume (1.2 mm) is slightly larger than the nominal FWHM of the mini-beams 
at a depth of 10 cm for SSD = 100 cm (1.1 mm).  This leads to some volume averaging across the 
mini-beam array, resulting in a reduced detector signal.  The SFD does not display this effect 
because its active volume is narrower than the mini-beams. 
 
5.6.4. Collimator Factor as a Function of Collimator Inclination 
 Figure 5.11 shows the measured collimator factor plotted against collimator inclination 
angle with respect to the beam central axis.  The measured collimator factors show a strong and 
nonlinear dependence on inclination angle.  Near alignment, the collimator factor is mostly 
insensitive to changes in inclination.  However, a greater dependence on changes in inclination is  
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Figure 5.11.  Measured collimator factor vs collimator inclination for each diode detector.  The 
values obtained from measurements of the unaligned fields are also shown. 
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observed when the collimator is further at greater angles.  The change in delivered dose as a 
function of collimator inclination was consistent on all three linacs, with a change in collimator 
inclination of 0.09o resulting in a clinically significant decrease in measured collimator factor of 
7.1% for each detector.  The differences incurred by changes in collimator alignment with respect 
to the beam central axis required that this effect be accounted for in the characterization process. 
 The original collimator factors (see Figure 5.10) are fitted within experimental uncertainty 
to the trends in Figure 5.11.  The initial inclination angles for each linac did not correspond to the 
relative magnitude of the measured collimator factor, and the difference persists at alignment. 
 
5.6.5. Aligned Dose Profiles 
 After the dependence on inclination was accounted for, the characterization measurements 
were repeated with the collimator aligned with the beam central axis.  The percent depth doses 
remained unchanged, as they depend mainly on beam energy, which is insensitive to the presence 
of the mini-beam collimator, as shown in Figure 5.8.  However, the dose profiles did respond to 
the collimator alignment, as shown in Figure 5.12.  Table 5.5 shows the new PVDR for each linear 
accelerator.  The lowest PVDR (Linac 3) and the highest PVDR (Linac 1) differ by >14%, with a 
maximum deviation from the mean of 8.1% in the case of Linac 1.   
Comparing the profiles shown in Figure 5.12 to the profiles prior to alignment in Figure 
5.9, it can be seen that failure to properly align the collimator for the linear accelerator results in a 
reduction in PVDR.  This decrease is particularly noticeable at the edges of the field, where the 
alignment of the divergence angle of the beam and collimator blades is poorest.  Similarly, 
deviation from 0o collimator inclination were found to result in asymmetric profiles.  This is most 
noticeable for Linac 1, the least aligned of the original measurements.  Due to the divergence of 
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Figure 5.12.  Dose profiles after collimator alignment at 10 cm depth normalized to the central 
axis dose on each linear accelerator.  The average of the dose profiles at 10 cm depth for the 
open field, as calculated by MEPHYSTO, is also shown.   
 
 
Linac PVDR 
1 1.595 ± 0.019 
2 1.472 ± 0.023 
3 1.414 ± 0.024 
 
Table 5.5.  The calculated peak-to-valley dose ratio and uncertainty for each linear accelerator. 
 
the blades, one half of the septa would be further from alignment than the other, resulting in greater 
apparent blade spacing, and therefore a larger PVDR on one side of the profile. When the 
collimator is properly aligned with the beam central axis, the profile will appear more symmetric, 
aside from differences arising from variation in the blade spacing incurred during fabrication. 
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5.6.6. Aligned Collimator Factors 
 The collimator factors at a collimator inclination of 0o with respect to the beam central axis 
was taken as the final measured collimator factor.  These measurements eliminate any variation 
due to collimator alignment, allowing for a more rigorous comparison.  The results continued to 
show the same trends that were observed for the unaligned collimator: being linear within the 
measurement uncertainty, and showing the disagreement across linear accelerators.   
 
5.6.6.1. Measured Collimator Factors 
 The final measured collimator factors and their uncertainties for each diode detector are 
shown in Figure 5.13.  Figure 5.13 clearly shows the persistent difference in measured collimator 
factor across the three linear accelerators, up to ±3.6% deviation from the mean collimator factor.  
In all cases, this difference is much greater than the measurement uncertainty.  In addition, it can 
be seen that the collimator factor retains the approximately linear dependence on the field side 
length. 
 
5.6.6.2. Mini-Beam Relative Output Factors 
The mini-beam relative output factors were calculated for each linear accelerator using the 
measured values for the open field relative output factor and the collimator factor.  Figure 5.14 
shows the mini-beam relative output factors for each measurement.  Due to the increase in relative 
output factor for larger open fields, the trend in the mini-beam relative output factor with respect 
to field size is inverted from that of the collimator factor, but remains linear within uncertainty.   
With one exception, the relative output factors do not agree to within experimental 
uncertainty.  As well, the measured relative output factors deviate from the mean by up to ±3.4%. 
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Figure 5.13.  Measured collimator factors for each diode detector.   
 
5.7. Discussion 
 These results reveal several features of the mini-beam collimator which must be considered 
before clinical use. 
 
5.7.1. Open Field Measurements 
 The good agreement between the open field measurements for all linear accelerators served 
to verify the clinical beam matching condition.  Therefore, the results of measurements on the 
different linacs can be compared directly.  This finding was expected, but verification was 
necessary in order to confirm that the mini-beam collimated fields could be directly compared. 
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Figure 5.14.  Relative output factors of the mini-beam collimated field for each diode detector. 
 
5.7.2. Percent Depth Dose and Dose Profile 
Figure 5.8 shows that the beam qualities of the four collimated fields agreed with the open 
field value within the clinical standard.  This was a desirable outcome, as it shows that the energy 
spectrum of the mini-beams was clinically indistinguishable to that of the open field.  This 
indicates that the mini-beam collimator has little effect on the energy spectrum of the photon beam, 
and is therefore suitable for the irradiation of targets well below the surface.  As such, the mini-
beam arrays could be used to deliver doses capable of tumour control to a target volume without 
delivering prohibitive doses to intervening tissue, one of the key advantages of MV energy MBRT.  
However, the electron contamination must be planned for to prevent excessive skin dose.     
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Figure 5.13 and Table 5.6 reveal the existence of differences in the mini-beam collimated 
fields generated by the three accelerators.  This outcome is unfavourable, since clinical differences 
in the collimated field across linacs may limit or complicate the transferability of the collimator.  
Due to this effect nominally clinically equivalent fields on different linacs will not deliver 
equivalent doses when used with the mini-beam collimator.  However, the peak dose can be fixed 
across linacs by varying the duration of the beam.  This linac dependence was also observed in the 
point dose measurements. 
 
5.7.3. Collimator Factors and Relative Output Factors 
 Figure 5.11 shows the rapid decrease in collimator factor due to small changes in collimator 
inclination angle with respect to the beam central axis.  This indicates that the collimator factor is 
highly sensitive to the collimator geometry, verifying the expectations from the design process.  
The collimator factor varied by an amount exceeding the beam matching tolerance in response to 
a change in inclination of less than the observed change in beam axis inclination across linear 
accelerators.  This effect must be characterized and controlled in order to deliver a consistent dose 
using the mini-beam collimated field.       
However, despite causing clinically significant variation, this effect does not account for 
the differences in collimator factor obtained on each medical linear accelerator.  As can be seen in 
Figure 5.11 and 5.13, the collimator factor measured with the collimator at 0o alignment varied 
across linacs by a clinically significant extent.  This indicates a difference between the linacs other 
than variation in beam steering or mechanical differences in the accessory mount. 
Another significant result is that the change in collimator factor across linacs follows the 
same trend as change in PVDR.  Equation 5.3 indicates that variation in peak dose would naturally 
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result in a proportional change in collimator factor.  The correlation observed in measurements 
indicates that the two features may be connected.   
It is clear that the mini-beam collimated fields on different linacs are dosimetrically 
distinct, despite the open fields being clinically beam matched.  However, the measured collimator 
factors for each linac were consistent across multiple experimental setups.  The consistency of the 
measured values and agreement between the corrected values for each individual linac indicate 
that the variation is a feature of the accelerators, and that proper dosimetric characterization must 
be pursued to allow for treatment planning and delivery of the mini-beam collimated fields for 
clinical purposes. 
 
The fact that the collimator factors and PVDR differ to such an extent across linear 
accelerators was unexpected.  The very small scale of the mini-beams appears to reveal differences 
between the linacs which are not apparent in the open field data. The next stage of the study was 
to identify the cause of this difference.  Direct testing of the suspected causes would have required 
alteration to the internal settings of the accelerators, requiring that the linacs be removed from 
clinical use until the commissioning data could be updated.  Instead, Monte Carlo simulations, 
which allowed fine and arbitrary control of the parameters being investigated, were used to test 
the hypotheses. 
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CHAPTER 6  
COLLIMATOR TRANSFERABILITY: 
MONTE CARLO SIMULATIONS 
 
As described in Chapter 4, Monte Carlo simulation can be a powerful tool for the study of 
radiation in matter.  By making use of simulations, it is possible to analyze the output of the 
collimated field without the mechanical or dosimetric constraints inherent in physical 
measurements.  Furthermore, simulations allow for the adjustment of accelerator settings without 
interfering with other uses of the accelerator.  The freedom to alter internal accelerator settings 
proved essential to identifying the cause of the disagreement in measured collimator factors.   
This chapter will provide a description of the process by which the simulations were 
performed.   The simulation results will be covered and discussed.  Finally, the process necessary 
to convert the measurements into values which can be used for treatment planning will be outlined, 
and the corrected values presented. 
 
6.1. Simulation Procedure 
The Monte Carlo simulations used to test the response to changes in linac parameters were 
carried out in three stages.  Simulations of the linacs were carried out in BEAMnrc to produce the 
collimated field and open field outputs using a model of a Varian iX medical linear accelerator 
head used in earlier studies of very small fields [23, 64, 66, 67, 68].  Subsequently, simulations of 
the resultant beams incident on a water phantom were used to simulate each of the experimental  
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Figure 6.1.  The simulated linac.  The simulated components and scoring planes for each stage of 
the simulation are labelled. 
 
measurements.  A representation of the simulated linac is depicted in Figure 6.1.  An example 
EGSnrc input file for each stage is provided in the Appendix. 
 
6.1.1. Stage 1: Treatment Head 
 The first stage in the modelling of the field was the simulation of the electron beam incident 
on the Bremsstrahlung target and the resultant photon fluence in BEAMnrc.  At this step, the 
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photons are generated by electron interactions with the target and transported through the internal 
components of the linear accelerator head.   
The incident 6.2 MeV electron beam was simulated as a circularly symmetric Gaussian 
source at the top surface (the surface facing towards the particle source) of the target.  Below the 
target, the primary collimator, flattening filter, monitor unit chamber, and mirror were modelled 
as component modules.  The beam head model used at this step terminated above the jaws, with a 
scoring plane located at the bottom of the mirror, 26.796 cm below the reference point and 26.8849 
cm below the electron source. 
1.0 x 108 electrons histories were used to simulate the incident beam.  The electrons 
incident on the target triggered Bremsstrahlung photon showers.  Directional Bremsstrahlung 
splitting was used to improve the efficiency of the simulation.  All photons within an 8 cm radius 
(defined at isocenter) splitting field were split 1000 times.  These photons were transported through 
the geometry of the treatment head to the scoring plane, just above the jaws.  The output of the 
simulation was the state of the particles at the scoring plane as a phase-space. 
 
6.1.2. Stage 2: Linac Field 
The next stage in the process was to simulate the field emitted from the medical linear 
accelerator in BEAMnrc.  At this step, the distinction between the mini-beam collimated field and 
open field simulations was established.  Unique inputs were made with and without the collimator 
to create representations of the mini-beam collimated and open fields. 
The phase-space resulting from the Treatment Head simulation was used as the particle 
source for these simulations.  These particles were transported through the jaws to the location of 
the accessory mount.  The field size of the simulation was defined using the jaw position.  For each 
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electron beam FWHM, inputs were made for four field sizes: 2 cm x 2 cm, 3 cm x 3 cm, 4 cm x 4 
cm, and 5 cm x 5 cm.   
Two inputs were made for each field size combination, one with the mini-beam collimator 
in place and one without.  The collimator was represented using the ARCCHM component module, 
which was intended for simulation of an arc-chamber attachment having a configuration similar to 
the collimator [56].  The component module consists of an array of alternating chambers and septa 
arranged in an arc.  The chamber and septa regions are defined by their chamber width and spacing 
and the front and back radii of the component module.  The walls of the component module define 
the limits of the arc-chamber.  A representation of the mini-beam collimator was created by setting 
the appropriate dimensions to match the collimator design.  For the collimated field input, the 
chambers were set to be tungsten, the walls aluminum, and the septa air.  For the open field input 
the component module was left in place, but all the media were set to be air.  This ensured 
consistency in the geometry of the two simulations. 
The inputs called for 4.5 x 108 particle histories from the Stage 1 phase-space.  The particles 
were transported through the jaws and collimator to the scoring plane 75 cm below the reference 
point.  Thus, the phase-space created at the scoring plane serves as a representation of the mini-
beam collimated field or open field. 
 
6.1.3. Stage 3: Dose Scoring 
 The final stage in the process was to simulate the linac output incident on the water 
phantom and detector.  The simulated collimator factor was determined from the results of 
simulations of the mini-beam collimated and open fields.  Thus, four unique simulations were 
required to obtain the collimator factor for both detectors in a given field.   
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 The DOSRZnrc simulation geometry at this step is a reconstruction of the experimental 
setup described in Chapter 5.  A 25 cm thick region of air is the intervening medium between the 
initial point of the beam and the simulated phantom.  The phantom consists of a region of water 
containing a model of the detector.  The detector is located such that the active volume is at 10 cm 
depth in the water, as was the case in the experimental setup.  The inputs are distinguished by the 
composition and geometry of the detector and the choice of input phase space.  The detector 
geometry also defined the simulation outputs, the dose deposited in the volume corresponding to 
the active volume of the detectors being the quantity of interest. 
 The simulation was set with a target uncertainty of ±0.5% and sufficient histories to satisfy 
this condition, generally 1.0 x 1010.  The particles in the Linac Field phase space were transported 
from their start point 25 cm above the water surface to their termination point.  Thus, the simulated 
collimator factor for each detector was obtained from the ratio of the dose deposited by the mini-
beam collimated field to the dose deposited by the open field. 
 DOSXYZnrc simulations were used to investigate the dose distribution of the fields.  As 
with the DOSRZnrc simulations, the simulated media consists of a 25 cm thick layer of air over a 
homogenous volume of water.  The detector was not included in the simulation geometry.  The 
region of interest in the water phantom was created out of voxels with a crossplane width of 0.2 
mm, equal to the crossplane resolution of the measured profiles.  The inplane and depth resolution 
were set to 1 mm and 1.5 mm.  The reduced resolution in these axes serves to reduce the 
computational requirements, as the resolution in this axis has minimal effect on the PVDR.  1.3 x 
109 particles from the Stage 2 phase space were used to represent the incident beam. Profiles at 10 
cm depth in the simulation phantom were constructed from the 3ddose file, and the PVDR was 
calculated as described by Equation 5.9. 
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6.2. Parameter Testing 
 The Monte Carlo simulations were carried out to test the effect of changes to linear 
accelerator parameters on the mini-beam collimated field so as to identify the cause of the variation 
described in Chapter 5.  Two features of the linacs were identified as plausible causes: the width 
of the initial electron beam incident on the Bremsstrahlung target and the separation between the 
source and the accessory mount holding the collimator.  Simulations for a range of reasonable 
values for these parameters were carried out to test these hypotheses. 
 
6.2.1. Electron Beam FWHM 
During the commissioning process, it was observed that the width of the initial electron 
source influenced the simulated collimator factor [23].  The width of the linac electron beam is 
nominally 1.0 mm, but is difficult to directly measure, and may vary.  Thus, it was hypothesized 
that differences in the width of the electron beam incident on the Bremsstrahlung target within 
each accelerator was responsible for the variation in PVDR and collimator factor across linacs.   
 In the open field configuration, small changes in the electron beam FWHM are acceptable.  
The source may differ in terms of area, but because the entire source is exposed the dose rate 
remains consistent.  However, the spacing of the blades in the collimator is narrower than the 
projection of the electron source.  When the collimator is in place, the source may be partially 
occluded by the blades, reducing the observable area of the electron.  The fraction of the source 
which is occluded by the collimator blades depends on the width of the electron source.  For greater 
electron beam FWHM, a larger percentage of the source is occluded, leading to a reduction in 
relative output factor for the mini-beam collimated field. 
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 The electron beam FWHM was manipulated in the first stage of the simulations by 
changing the FWHM of the electron source in the Stage 1 simulation.  The full simulation process 
was carried out for electron beam FWHMs from 0.7 mm to 1.2 mm at 0.1 mm intervals.  As an 
initial test of the effect, the simulations were carried out for the 4 cm x 4 cm mini-beam collimated 
field and open field incident on both detectors.  Subsequently, additional simulations were carried 
out for 2 cm x 2 cm, 3 cm x 3 cm, and 5 cm x 5 cm fields incident on both detectors.  Finally, 
DOSXYZnrc simulations of the 4 cm x 4 cm field for each electron beam FWHM were used to 
construct dose profiles to determine the PVDR of the simulated mini-beam collimated field as a 
function of FWHM. 
 
6.2.2. Source-to-Collimator Distance 
Another feature that may differ across medical linear accelerators is the distance between 
the beam source and the collimator in the accessory mount.  Though this distance is expected to 
agree between any two linear accelerators to a tolerance of ±1 mm, wear over the varied service 
lives of the linacs may induce differences in the accessory mounts. 
As described in Section 5.6.4, the mini-beam collimated field is highly sensitive to changes 
in the blade spacing of the mini-beam collimator.  As the collimator was designed such that the 
blades align to the beam divergence at the height of the accessory mount, raising or lowering the 
collimator will cause a change in the alignment of the blades relative to the beam divergence.   
The collimator height was varied in the Stage 2 simulations by varying the height of the 
ARCCHM component module in 0.1 cm steps for 0.5 cm above and below the nominal position 
of 58.9 cm from the source.  DOSRZnrc simulations were carried out for the 4 cm x 4 cm field 
incident on both detectors as a test of the effect.   
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6.3. Results of Parameter Testing 
 The hypothesized causes of the discrepancies were tested by studying the relationship 
between the simulated collimator factor and PVDR and the parameter of interest. 
 
6.3.1. Collimator Factor and PVDR as a Function of Electron Beam FWHM 
 DOSRZnrc simulations for all field sizes using both detectors were carried out to obtain 
collimator factors for a range of electron beam widths.  The results were observed to cover the 
range of measured collimator factors obtained by the experimental measurements and shown in 
Figure 5.14.  As such, it was possible to fit the experimental data to the simulation trends in order 
to determine the electron beam FWHM of each linear accelerator.  The eight measured values for 
each linac were fitted to the interpolated trend between the two nearest simulated collimator factors 
by the method of least squares regression.  The simulated and measured collimator factors are 
plotted against electron beam FWHM in Figure 6.2.  The experimental data can be seen to fit the 
simulation results within the calculated uncertainty.  The electron beam FWHMs obtained from 
the data are stated in Table 6.1.  
 DOSXYZnrc simulations served to determine the PVDR as a function of electron beam 
FWHM.  The simulated PVDR for each FWHM are shown in Figure 6.2.  As expected, the PVDR 
decreases with increasing electron beam FWHM.  The measured PVDR for each linac (Table 5.5) 
are shown at the fitted FWHM stated in Table 6.1.  All values fit the trend of simulated PVDR 
within the calculated uncertainty, and agree with the simulated PVDR to within ±1.2% along the 
trend line obtained by linear interpolation. 
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Figure 6.2.  Collimator Factors vs Electron Beam FWHM.  The measured collimator factors for 
each detector are shown at fitted linac-specific electron beam FWHM.  Simulated collimator 
factors are shown in gray, and experimental collimator factors are shown in colour. 
 
Linac Electron Beam FWHM (mm) 
1 0.82 
2 0.98 
3 1.07 
 
Table 6.1.  Fitted electron beam FWHMs for Linacs 1-3. 
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Figure 6.3. PVDR vs Electron Beam FWHM.  The measured PVDR for each detector are shown 
at the previously fitted electron beam FWHM.  Simulated PVDR are shown in gray and 
experimental PVDR are shown in colour. 
 
6.3.2. Collimator Factor as a Function of Source to Collimator Distance 
 Simulations of the mini-beam collimated field revealed minimal change in the collimator 
factor as a function of any plausible change in the distance between the Bremsstrahlung target and 
the mini-beam collimator.  Figure 6.4 shows the simulated collimator factors obtained for all 
collimator to source distances.  As can be seen, all simulated collimator factors are equal to within 
the calculated uncertainty.  Thus, the vertical position of the mini-beam collimator has no 
noticeable effect of the simulated collimator factor. 
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Figure 6.4.  Simulated collimator factors versus source-to-collimator distance for a 4 cm x 4 cm 
field.  
 
6.4. Mini-Beam Correction Factors 
High-resolution diode detectors have been shown to over-respond relative to the dose to 
water in very small fields [67, 69, 70].  A correction must be applied to dose measurements of 
small fields, such as the mini-beams, in order to account for this effect [71].  When the dose ratios 
for small fields are calculated, this correction (𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 ) can be applied such that:  
𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 = 𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 ∗ 𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 ,                                          (6.1)           
and it follows that Equation 5.2 can be found by: 
𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 = 𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑤 ∗ 𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 ∗ 𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 ,                                 (6.2)           
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The correction factors can be calculated by Monte Carlo simulation of the mini-beam collimated 
field and open field incident on the detector of interest and homogenous water phantom via: 
𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 =
(
 
 
(
𝐷𝑓𝑚𝑖𝑛𝑖
𝑤
𝐷𝑓𝑐𝑙𝑖𝑛
𝑤 )
(
𝐷𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡
𝐷𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 )
)
 
 
𝑀𝐶
.                                        (6.3)           
The correction factors are dependent on the geometry and composition of the detector.  Therefore, 
different detectors each have different correction factors. 
When applying the correction factor to obtain 𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤  and 𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 , Equations 5.10 and 5.11 
can be rewritten to account for the uncertainty in the correction, such that: 
𝑢𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 = √(𝑢𝐶𝐹𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 )
2
+ (𝑢𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 )
2
                               (6.4)          
and 
 
𝑢𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 = √(𝑢𝑂𝐹𝑓𝑐𝑙𝑖𝑛
𝑑𝑒𝑡 )
2
+ (𝑢𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 )
2
+ (𝑢𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡 )
2
.               (6.5)           
 
6.4.1. Calculation 
 As described in Equation 6.3, a correction for the effects of the detector geometry can be 
determined using Monte Carlo simulation of the mini-beam collimated field.   Four values were 
necessary to obtain each correction factor: the DOSRZnrc outputs for both the mini-beam 
collimated and open fields incident on a water phantom with and without the detector.  A unique 
correction factor was calculated for each field and electron beam FWHM.  After the variation 
across linacs was linked to electron beam FWHM, simulations using the linac specific FWHM  
95 
 
 Linac 1 Linac 2 Linac 3 
Field (cm2) PTWe SFD PTWe SFD PTWe SFD 
5 x 5 
1.054  
± 0.008  
0.984 
± 0.008 
1.044 
± 0.008 
0.986 
± 0.008 
1.035 
± 0.005 
0.982 
± 0.006 
4 x 4 
1.060 
± 0.007 
0.986 
± 0.007 
1.039 
± 0.007 
0.978 
± 0.008 
1.038 
± 0.006 
0.981 
± 0.006 
3 x 3 
1.050 
± 0.006 
0.976 
± 0.007 
1.042 
± 0.006 
0.984 
± 0.006 
1.035 
± 0.005 
0.979 
± 0.006 
2 x 2 
1.053 
± 0.005 
0.978 
± 0.006 
1.046 
± 0.005 
0.986 
± 0.007 
1.035 
± 0.005 
0.975 
± 0.005 
 
Table 6.2. Linac-specific correction factors with calculated uncertainty for each field and detector. 
 
were carried out to obtain dose to  water for each linac.  The correction factors, stated in Table 6.2, 
were calculated via simulation of the fields generated for the FWHM stated in Table 6.1.  Note 
that the PTWe correction is consistently greater than 1, while the SFD correction factor is 
consistently less than 1.  This shows that the PTWe under-responds to the mini-beam collimated 
field, despite the diode detector over-response in very small fields.  As with the previous difference 
between the PTWe and SFD, this is a result of the greater diameter of the PTWe active volume. 
 
6.4.2. Corrected Collimator Factors 
The 𝑘𝑓𝑚𝑖𝑛𝑖
𝑑𝑒𝑡  were applied to the measured collimator factors from Figure 5.13 to obtain the 
collimator factors in water.  Figure 6.5 shows the collimator factors in water for each linear 
accelerator.  The correction factors eliminate the difference between the measured collimator 
factors for each detector, bringing the measurements for each linac into agreement within the 
calculated uncertainty.  The corrected collimator factors for certain fields show agreement within 
experimental uncertainty (e.g. 3 cm x 3 cm for Linacs 2 and 3).   
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Figure 6.5.  Collimator factors in water (𝐶𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 ) for each linear accelerator. 
 
6.4.3. Corrected Mini-Beam Relative Output Factors 
 The collimator factors in water were used to calculate the mini-beam relative output in 
water.  These corrected relative output factors are shown in Figure 6.6.  𝐶𝐹𝑓𝑚𝑖𝑛𝑖(5𝑥5)
𝑤  is equal to 
𝑂𝐹𝑓𝑚𝑖𝑛𝑖(5𝑥5)
𝑤  for all linacs because the 5 cm x 5 cm field was used as the reference field.   
The relative output factors in water for each detector agree within experimental uncertainty.  
Once again, agreement between some values on different linacs can be observed, but no two linacs 
agree within the calculated uncertainty for all fields. 
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Figure 6.6.  Mini-beam relative output factors in water (𝑂𝐹𝑓𝑚𝑖𝑛𝑖
𝑤 ) for each diode detector. 
 
6.5. Discussion 
 The Monte Carlo simulations offered greater insight into the factors influencing the mini-
beam collimated field. 
 
6.5.1. Parameter Testing 
 The simulations strongly indicate that the discrepancies between the mini-beam collimated 
fields are linked to variation in the FWHM of the linac electron beam incident on the 
Bremsstrahlung target.  The experimental results were successfully fitted to simulated collimator 
factors.  With few exceptions, the measured collimator factors show agreement with the simulated  
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 Linac 1 Linac 2 Linac 3 
Field (cm2) 𝐂𝐅𝐦𝐢𝐧𝐢
𝐰  𝐎𝐅𝐟𝐦𝐢𝐧𝐢
𝐰  𝐂𝐅𝐦𝐢𝐧𝐢
𝐰  𝐎𝐅𝐟𝐦𝐢𝐧𝐢
𝐰  𝐂𝐅𝐦𝐢𝐧𝐢
𝐰  𝐎𝐅𝐟𝐦𝐢𝐧𝐢
𝐰  
5 x 5 
0.459 
± 0.010 
0.459 
± 0.012 
0.442 
± 0.011 
0.442 
± 0.010 
0.430 
± 0.008 
0.430 
± 0.007 
4 x 4 
0.467 
± 0.010 
0.449 
± 0.010 
0.445 
± 0.011 
0.428 
± 0.009 
0.436 
± 0.009 
0.420 
± 0.009 
3 x 3 
0.469 
± 0.009 
0.433 
± 0.009 
0.452 
± 0.009 
0.417 
± 0.008 
0.440 
± 0.008 
0.406 
± 0.008 
2 x 2 
0.477 
± 0.008 
0.420 
± 0.008 
0.459 
± 0.009 
0.405 
± 0.007 
0.445 
± 0.007 
0.392 
± 0.007 
 
Table 6.3. Average corrected collimator factors and mini-beam relative output factors with 
calculated uncertainties for each linac. 
 
trends within measurement uncertainty, and all measured collimator factors agreed with the 
simulated trends within the interpolated simulation uncertainty.  Similarly, the measured PVDR 
were in agreement with the trend of simulated PVDR.  Thus, the established Monte Carlo model 
of the linear accelerator can be matched to any particular characterized linac by setting the initial 
electron beam FWHM appropriately. 
 The collimator factor was found to be insensitive to variation in source-to-collimator 
distance over a 5 mm in either direction from the nominal distance.  Any change of this magnitude 
due to the accessory mount position would be detected during annual inspection of the isocenter 
position, being five times greater than the TG-142 tolerance [62]. 
 
6.5.2. Corrected Collimator Factors and Relative Output Factors 
The diode correction factors brought the measured collimator factor and mini-beam relative 
output factor for each linear accelerator into agreement.  Due to the agreement within uncertainty 
of the corrected values, the average of the two detector-measured values for each field can be taken 
to give a single value.  The averages are stated in Table 6.3.  The calculated uncertainties of all 
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values are less than 3.0%, sufficient for clinical repeatability.  These average corrected values can 
be used as the primary characterization metric of the mini-beam collimated field on the different 
linear accelerators.  Furthermore, the effectiveness of the correction factors serves as additional 
verification of the accuracy of the model, as it produced valid correction factors over a range of 
initial parameters. 
 
 The results of the Monte Carlo simulations provide an explanation for the variation 
observed in the experimental measurements.  Though the characterization metrics for individual 
linacs do not agree within the beam matching criterion, the simulations show that this discrepancy 
stems from a feature of the linacs, and can be expected to remain consistent over time.  Thus, use 
of the mini-beam collimator will produce a consistent field. 
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CHAPTER 7 
CONCLUSION 
 
 A mini-beam collimator intended to deliver high-energy mini-beam radiotherapy using 
standard medical linear accelerators has been developed by a group at the Saskatoon Cancer 
Centre.  The goal of this work was the dosimetric characterization of the mini-beam collimator on 
multiple beam matched medical linear accelerators.  Experimental measurements and Monte Carlo 
simulations were used to accomplish this goal. 
 
7.1. Transferability 
The experimental characterization of the mini-beam collimated field involved 
measurements of percent depth dose curves, dose profiles, and dose to a reference point at 10 cm 
depth in water.  Two diode detectors were used in the measurements. The measurements were 
performed on three clinically beam matched medical linear accelerators using the 6 MV beam 
energy.  Corresponding measurements of the open field verified the beam matching criteria and 
provided a reference point for comparison with the mini-beam collimated field. 
%DD measurements were performed on all three linacs.  All results showed close 
agreement in both %DD(10 cm) and dmax.  As well, the results were consistent with the 
measurements of the open field.  These results show that the mini-beam collimator has minimal 
impact of the energy spectrum of the field, such that the nominal energy of each mini-beam 
remains equivalent to that of the open field.  Thus, the mini-beams exhibit the same attenuation 
characteristics. 
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Crossplane dose profiles of the mini-beam collimated field were measured for all three 
linacs.  The PVDR varied to a clinically significant degree across linacs.  A linac dependence was 
also observed in the collimator factor, calculated from the point doses obtained in the mini-beam 
collimated field and open field.  The collimator factors on each linac were proportional to the 
PVDR, suggesting that they stem from the same root cause.  This difference between linear 
accelerators complicates the use of the mini-beam collimator, necessitating the full 
characterization of the mini-beam collimated field on each linac before use.  
However, while the PVDR and magnitude of the collimator factor varied across linacs, 
several other features were found to be linac-independent.  The effect of changes in all controllable 
parameters, most notably field size, on the mini-beam collimated field to was consistent across 
linacs.  Thus, the mini-beam collimated field delivered on each linac remains consistent across 
multiple experimental sessions. 
A feature that must be noted when setting the mini-beam collimator is the collimator 
inclination angle relative to the beam central axis.  The mini-beam collimated field shows a strong 
dependence on collimator inclination.  There exists a narrow range where the collimator factor 
remains constant before rapidly decreasing with increased deviation from the optimum inclination 
angle. This dependence on collimator inclination angle must be accounted for when transferring 
the mini-beam collimator between linacs.  
EGSnrc modelling of the mini-beam collimated field was used to identify the cause of the 
variation observed in the experimental results.  BEAMnrc simulations were used to generate phase 
spaces representing a field corresponding to each set of linac parameters.  DOSRZnrc simulations 
were used to calculate the collimator factor for each detector in each field for a range of electron 
beam FWHM.  Similarly, DOSXYZnrc simulations were used to determine the PVDR as a 
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function of electron beam width.  The results showed that variation in the FWHM of the linac 
electron beam could account for the observed variation in collimator factor and PVDR. 
By fitting the measured collimator factors to the simulated values, electron beam FWHM 
for each linac were predicted.  Correction factors to eliminate detector specific effects in the 
measured collimator factors were calculated for each electron beam FWHM by taking the ratio of 
the simulated collimator factor in water to that in the detector.  Applying these correction factors 
to the measured values eliminated the discrepancy introduced by the detector small field effects.  
Thus, a single collimator factor for each linac and field was obtained.  The efficacy of these 
correction factors serves to validate the mini-beam collimated field models. 
With the mini-beam collimated field characterized and the EGSnrc model validated, the 
mini-beam collimator may be utilized in the same way as any linac accessory. It is now possible 
to establish a procedure for characterization of the mini-beam collimator. 
 
7.2. Recommended Procedure for Characterization 
 While the mini-beam collimated field for each linac is consistent when properly used, 
thorough characterization is necessary due to the differences between linacs.  The following 
procedure is based on the experience gained from this transferability study. 
 First, a baseline lateral position and inclination angle for the collimator must be set.  This 
setting must be carried out with the collimator mounted on a linac, because inserting or removing 
the collimator from the accessory mount influences the micrometer reading.  The collimator should 
be returned to this position when not is use on another linac. 
After the baseline setting is established, the next step is determining the proper collimator 
position on the new linac.  The mini-beam collimator should first be centered in the field, followed 
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by aligning the collimator inclination to the beam central axis.  The process for these adjustments 
are described in Section 5.3.3 and Section 5.3.4, respectively.  The initial and final positions 
measured by the micrometer for each of these steps must be recorded.  These offsets will be used 
to set the collimator position for the linac in the future. 
 With the collimator aligned, measurements of the collimator factor must be carried out as 
described in Section 5.5.  The measured collimator factors should then be fitted to a range of 
simulated collimator factors for the detector used in commissioning to determine the linac electron 
beam FWHM.  A BEAMnrc simulation input using this electron beam FWHM should then be 
made for planning purposes. 
 Regular quality assurance must be used to ensure the positional settings of the mini-beam 
collimator do not change in the course of use.  Unlike the full characterization, this does not 
necessarily require the precision of the water phantom; any test apparatus (e.g. solid water) with a 
previously determined response can be used.  If the dose to the reference point in the mini-beam 
collimated field agrees with the nominal value within clinical requirements, the mini-beam 
collimator settings for that linac remain valid.  Any significant reduction in this dose is cause to 
repeat the alignment procedure for the collimator.  In this event, the mini-beam collimated field 
on all linacs must be checked for agreement before further use of the collimator. 
In addition, the characterization measurements must be repeated periodically to obtain up-
to-date micrometer readings.  These measurements could be integrated into an  annual QA 
procedure. 
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7.3. Related Work 
 While the collimated field has been shown to be reliable, it will not be adopted for clinical 
use unless the clinical benefits can be verified.  With the dosimetric characterization of the mini-
beam collimated field complete, other studies are being carried out to examine biological response 
to the mini-beam collimated field. 
 A study of the response of cells to mini-beam and open field radiation is being carried out 
in conjunction with the University of Saskatchewan Cancer Cluster [72].  This work will serve to 
assess the radiobiology of MV energy MBRT.  Irradiation of two glioblastoma cell lines and a 
control cell line are being used to examine the radiation effects as a function of both dose and time 
is being carried out.  Cell survival fractions as a function of dose and of time were obtained, and 
occurrences of the modes of radiation damage (e.g. apoptosis, nuclear damage) are being 
investigated. 
 A study of the efficacy of mini-beam treatments of canines is being carried out with the 
Western College of Veterinary Medicine [73].  Sixteen dogs with spontaneous brain tumours are 
selected from the available patients and randomly assigned treatment with conventional 
radiotherapy or MBRT.  The health of the dogs is tracked for the remainder of their lives.  After 
the patient dies, post-mortem analysis of the irradiated regions will be carried out to examine the 
brain for signs of radiation damage. 
 
 A collimator accessory which allows the delivery of spatially-fractionated mini-beam 
treatment was developed by a group at the Saskatoon Cancer Centre.  The mini-beam collimator 
has been dosimetrically characterized on three beam matched linear accelerators.  Dosimetric 
differences between the mini-beam collimated fields delivered on each linac were observed.  By 
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varying the parameters of an EGSnrc model of the collimated field, these differences were traced 
back to variation in the FWHM of the electron beam incident on the Bremsstrahlung target.  This 
finding is a step towards the planning of mini-beam collimated fields across multiple linacs, and 
forms a basis for expanded use of the mini-beam collimator.  Thus, transferability of the mini-
beam collimator can be attained by the thorough dosimetric characterization of the mini-beam 
collimated field. 
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APPENDIXA 
EXAMPLE EGSnrc INPUT FILES 
Examples of the input files used for each step of the simulation process (described in 
Chapter 6) are provided here.  Significant lines or sections are indicated by bold font. 
 
A.1. BEAMnrc Input for the Treatment Head 
 The input at this stage served to create the photons that constitute the beam.  Note Line 6 
of the input, which specifies the source.  The simulation calls an elliptical (ISOURCE = 19) 
electron (IQIN = -1) source with a Gaussian FWHM of 0.09 cm (RBEAM = -0.09) and zero 
eccentricity (RBEAMY = 0).  The number of photons generated by electron interactions with the 
target is increased via the use of Directional Bremsstrahlung splitting (DBS).  The DBS options 
are specified in Line 5.  As well, Line 4 specifies the number of histories and RNG seeds, and Line 
8 specifies the initial energy of the electrons.  The simulation geometry is defined in the subsequent 
Component Modules.  Line 11 specifies that particles be scored to the phase space below the sixth 
component module, MIRROR.  The transport settings are specified following the component 
modules [56]. 
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Varian iX 6MV at 6.2 MeV with FWHM=0.09 cm                                        #!GUI1.0 
 
AIR521ICRU 
0, 0, 0, 0, 0, 1, 0,  IWATCH ETC. 
100000000, 33, 97, 999, 2, 1000, 0, 0,  NCASE ETC. 
8, 100, 0, 20, 1, 12.7,  DIRECTIONAL BREM OPTIONS 
-1, 19, -0.09, 0, 0, 0, 0.0, -, 0.0, 0.0,  IQIN, ISOURCE + OPTIONS 
0, MONOENERGETIC 
6.2 
0, 0, 0.521, 0.01, 0, 0, ,  0 , ECUT,PCUT,IREJCT,ESAVE 
0, 0, 0, 0, 0,  PHOTON FORCING 
1, 6,  SCORING INPUT 
0,1 
0,  DOSE COMPONENTS 
-0.0889, Z TO FRONT FACE 
*********** start of CM SLABS with identifier target  *********** 
10, RMAX 
Target 
2, NSLABS 
-0.0889, ZMIN 
0.0889, 0, 0, 0, 1, -1 
W521ICRU 
0.1575, 0, 0, 0, 2, -1 
CU521ICRU 
*********** start of CM CONS3R with identifier pri_coll  *********** 
10, RMAX 
pri_coll 
0.1575, ZMIN 
7.3725, ZTHICK 
4, NUM_NODE 
0.1575, 2.5,  
1.54, 2.5,  
1.54, 0.613,  
7.53, 2.09,  
0, 0, 0, 3, -1,  
VACUUM 
0, 0, 0, 4, -1,  
WLIGHT 
*********** start of CM SLABS with identifier be_win  *********** 
10, RMAX 
AIR GAP 
2, NSLABS 
7.53, ZMIN 
0.94, 0.521, 0.01, 0, 5, 0 
VACUUM 
0.0254, 0.521, 0.01, 0, 6, 0 
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BE521ICRU 
*********** start of CM FLATFILT with identifier fla_filt  *********** 
10, RMAX 
FLATFILT 
10.485, ZMIN 
19, NUMBER OF LAYERS 
1, 0.028, # CONES, ZTHICK OF LAYER 1 
0.0,  
0.064,  
1, 0.028, # CONES, ZTHICK OF LAYER 2 
0.064,  
0.127,  
1, 0.038, # CONES, ZTHICK OF LAYER 3 
0.127,  
0.191,  
1, 0.041, # CONES, ZTHICK OF LAYER 4 
0.191,  
0.254,  
1, 0.074, # CONES, ZTHICK OF LAYER 5 
0.254,  
0.381,  
1, 0.1535, # CONES, ZTHICK OF LAYER 6 
0.381,  
0.508,  
1, 0.1235, # CONES, ZTHICK OF LAYER 7 
0.508,  
0.635,  
1, 0.1235, # CONES, ZTHICK OF LAYER 8 
0.635,  
0.762,  
1, 0.1235, # CONES, ZTHICK OF LAYER 9 
0.762,  
0.889,  
1, 0.1135, # CONES, ZTHICK OF LAYER 10 
0.889,  
1.016,  
1, 0.2235, # CONES, ZTHICK OF LAYER 11 
1.016,  
1.27,  
1, 0.2035, # CONES, ZTHICK OF LAYER 12 
1.27,  
1.524,  
1, 0.2035, # CONES, ZTHICK OF LAYER 13 
1.524,  
1.778,  
1, 0.1835, # CONES, ZTHICK OF LAYER 14 
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1.778,  
2.032,  
1, 0.1735, # CONES, ZTHICK OF LAYER 15 
2.032,  
2.286,  
1, 0.142, # CONES, ZTHICK OF LAYER 16 
2.286,  
2.54,  
1, 0.13, # CONES, ZTHICK OF LAYER 17 
2.54,  
2.794,  
3, 0.097, # CONES, ZTHICK OF LAYER 18 
2.794, 3.366, 3.81,  
3.061, 3.302, 3.81,  
1, 0.165, # CONES, ZTHICK OF LAYER 19 
3.81,  
3.81,  
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0.521, 0.01, 0, 7,  
CU521ICRU 
0.521, 0.01, 0, 8,  
AIR521ICRU 
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0, 0, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
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CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0.521, 0.01, 0, 7,  
CU521ICRU 
0.521, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
0.521, 0.01, 0, 7,  
CU521ICRU 
0.521, 0.01, 0, 8,  
AIR521ICRU 
0.521, 0.01, 0, 7,  
CU521ICRU 
0.521, 0.01, 0, 8,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 7,  
AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0, 0, 8,  
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AIR521ICRU 
0, 0.01, 0, 7,  
CU521ICRU 
0, 0.01, 0, 8,  
AIR521ICRU 
*********** start of CM CHAMBER with identifier ion_cham  *********** 
10, RMAX 
Ion Chamber 
14.2, ZMIN 
0, 15, 0, N_TOP, N_CHM, N_BOT 
4.7625, 4.7752, 4.95, RADII FOR CENTRAL PART 
0.629, 0, ZTHICK, FLAG FOR LAYER 1 IN CENTRAL PART 
0, 0.01, 0, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 2 IN CENTRAL PART 
0, 0.01, 0, 0,  
KAPTON521ICRU 
0.229, 0, ZTHICK, FLAG FOR LAYER 3 IN CENTRAL PART 
0, 0, 1, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 4 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.234, 0, ZTHICK, FLAG FOR LAYER 5 IN CENTRAL PART 
0, 0, 2, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 6 IN CENTRAL PART 
0, 0, 0, 0,  
KAPTON521ICRU 
0.229, 0, ZTHICK, FLAG FOR LAYER 7 IN CENTRAL PART 
0.521, 0.01, 3, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 8 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.299, 0, ZTHICK, FLAG FOR LAYER 9 IN CENTRAL PART 
0.521, 0.01, 4, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 10 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.233, 0, ZTHICK, FLAG FOR LAYER 11 IN CENTRAL PART 
0.521, 0.01, 5, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 12 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
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KAPTON521ICRU 
0.23, 0, ZTHICK, FLAG FOR LAYER 13 IN CENTRAL PART 
0.521, 0.01, 6, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 14 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.628, 0, ZTHICK, FLAG FOR LAYER 15 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 9,   chamber wall 
AIR521ICRU 
0.521, 0.01, 0, 10,   gap 
AIR521ICRU 
0.521, 0.01, 0, 11,   container 
AIR521ICRU 
0, MRNGE 
*********** start of CM MIRROR with identifier mirror  *********** 
10, RMAX 
MIRROR 
18.873, 7.923, ZMIN, ZTHICK 
4.67, -6.645, XFMIN, XBMIN 
1, # LAYERS 
0.00508,  thickness of layer 1 
0.521, 0.01, 0, 12,  
MYLAR521ICRU 
0.521, 0.01, 0, 13,  
AIR521ICRU 
0.521, 0.01, 0, 14,  
AIR521ICRU 
*********************end of all CMs***************************** 
 ######################### 
 :Start MC Transport Parameter:  
 
 Global ECUT= 0.521 
 Global PCUT= 0.01 
 Global SMAX= 5 
 ESTEPE= 0.25 
 XIMAX= 0.5 
 Boundary crossing algorithm= PRESTA-I 
 Skin depth for BCA= 0 
 Electron-step algorithm= PRESTA-II 
 Spin effects= On 
 Brems angular sampling= Simple 
 Brems cross sections= BH 
 Bound Compton scattering= Norej 
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 Compton cross sections= default 
 Pair angular sampling= Simple 
 Pair cross sections= BH 
 Photoelectron angular sampling= Off 
 Rayleigh scattering= Off 
 Atomic relaxations= On 
 Electron impact ionization= Off 
 Photon cross sections= si 
 Photon cross-sections output= Off 
  
 :Stop MC Transport Parameter: 
 ######################### 
 :Start DBS rejection plane:  
 
 Use a rejection plane= On 
 Z(cm) from zero reference plane= 26.78  
 
 :Stop DBS rejection plane: 
 ######################### 
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A.2. BEAMnrc Input for the Linac Field 
 The input at this stage transported the Bremsstrahlung photons through the jaws and mini-
beam collimator.  The simulation parameters are defined in the same way as in the first stage.  At 
this stage, particles are called from the phase space file generated in the first stage instead of being 
produced on demand (ISOURCE = 21).  DBS is not used in this simulation.  The X and Y settings 
of CM JAWS define the field. CM ARCCHM represents the mini-beam collimator, with the 
chambers (CHM) corresponding to the blades and the septa (SEP) to the air gaps [56].  Note that 
the MIRROR and CHAMBER component modules are included in this simulation geometry to 
account for backscatter within the treatment head. This input is for a mini-beam collimated field, 
and includes the aluminum (AL521ICRU) and tungsten (W521ICRU) components.  These 
components are set as air (AIR521ICRU) for the open field input.  The scoring plane is below the 
ARCCHM module 
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Minibeam with Jaws, correlated to measurements                                   #!GUI1.0 
 
AIR521ICRU 
0, 0, 0, 0, 0, 1, 0,  IWATCH ETC. 
452302612, 33, 97, 99, 0, 0, 0, 0,  NCASE ETC. 
9, 21, 3, 0, 0, 0, 0, 0, 0, 0,  IQIN, ISOURCE + OPTIONS 
../BEAM_varian_6x_above_jaws/0_090eSource_SYMM.egsphsp1 
0, 0, 0.521, 0.01, 0, 0, ,  0 , ECUT,PCUT,IREJCT,ESAVE 
0, 0, 0, 0, 0,  PHOTON FORCING 
1, 4,  SCORING INPUT 
0,1 
0,  DOSE COMPONENTS 
12.853, Z TO FRONT FACE 
*********** start of CM CHAMBER with identifier ion_cham  *********** 
10, RMAX 
Ion Chamber 
14.2, ZMIN 
0, 15, 0, N_TOP, N_CHM, N_BOT 
4.7625, 4.7752, 4.95, RADII FOR CENTRAL PART 
0.629, 0, ZTHICK, FLAG FOR LAYER 1 IN CENTRAL PART 
0, 0.01, 0, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 2 IN CENTRAL PART 
0, 0.01, 0, 0,  
KAPTON521ICRU 
0.229, 0, ZTHICK, FLAG FOR LAYER 3 IN CENTRAL PART 
0, 0, 1, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 4 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.234, 0, ZTHICK, FLAG FOR LAYER 5 IN CENTRAL PART 
0, 0, 2, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 6 IN CENTRAL PART 
0, 0, 0, 0,  
KAPTON521ICRU 
0.229, 0, ZTHICK, FLAG FOR LAYER 7 IN CENTRAL PART 
0.521, 0.01, 3, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 8 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.299, 0, ZTHICK, FLAG FOR LAYER 9 IN CENTRAL PART 
0.521, 0.01, 4, 0,  
AIR521ICRU 
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0.0051, 0, ZTHICK, FLAG FOR LAYER 10 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.233, 0, ZTHICK, FLAG FOR LAYER 11 IN CENTRAL PART 
0.521, 0.01, 5, 0,  
AIR521ICRU 
0.0051, 0, ZTHICK, FLAG FOR LAYER 12 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.23, 0, ZTHICK, FLAG FOR LAYER 13 IN CENTRAL PART 
0.521, 0.01, 6, 0,  
AIR521ICRU 
0.0127, 0, ZTHICK, FLAG FOR LAYER 14 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
KAPTON521ICRU 
0.628, 0, ZTHICK, FLAG FOR LAYER 15 IN CENTRAL PART 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 9,   chamber wall 
AIR521ICRU 
0.521, 0.01, 0, 10,   gap 
AIR521ICRU 
0.521, 0.01, 0, 11,   container 
AIR521ICRU 
0, MRNGE 
*********** start of CM MIRROR with identifier mirror  *********** 
10, RMAX 
MIRROR 
18.873, 7.923, ZMIN, ZTHICK 
4.67, -6.645, XFMIN, XBMIN 
1, # LAYERS 
0.00508,  thickness of layer 1 
0.521, 0.01, 0, 12,  
MYLAR521ICRU 
0.521, 0.01, 0, 13,  
AIR521ICRU 
0.521, 0.01, 0, 14,  
AIR521ICRU 
*********** start of CM JAWS with identifier jaws  *********** 
10, RMAX 
jaws 
2, # PAIRED BARS OR JAWS 
X 
28.0, 35.8, 0.56000, 0.71600, -0.56000, -0.71600,  
Y 
36.7, 44.5, 0.73400, 0.89000, -0.73400, -0.89000,  
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0.521, 0.01, 0, 0,  
0.521, 0.01, 0, 0,  
W521ICRU 
0.521, 0.01, 0, 0,  
W521ICRU 
*********** start of CM ARCCHM with identifier minibeam  *********** 
100, RMAX 
Column 
58.9, ZSRC 
60, ZRAD1 
34, NUMBER OF CHAMBERS 
0.06, WIDTHCHM 
0.044, WIDTHSEP 
10, ARCTHICK 
5e-7, FRONTHCK 
5e-7, BACKTHCK 
0.84, WIDTH OF X WALL 
-20, 20, XMIN1 XMAX2 
75, ZMAX 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 0,  
AL521ICRU 
0.521, 0.01, 0, 0,  1 
W521ICRU 
0.521, 0.01, 0, 0,  1 
AIR521ICRU 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 0,  
AIR521ICRU 
0.521, 0.01, 0, 0,  
AL521ICRU 
*********************end of all CMs***************************** 
 ######################### 
 :Start MC Transport Parameter:  
 
 Global ECUT= 0.521 
 Global PCUT= 0.01 
 Global SMAX= 5 
 ESTEPE= 0.25 
 XIMAX= 0.5 
 Boundary crossing algorithm= EXACT 
 Skin depth for BCA= 0 
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 Electron-step algorithm= PRESTA-II 
 Spin effects= On 
 Brems angular sampling= Simple 
 Brems cross sections= BH 
 Bound Compton scattering= Norej 
 Compton cross sections= default 
 Pair angular sampling= Simple 
 Pair cross sections= BH 
 Photoelectron angular sampling= Off 
 Rayleigh scattering= Off 
 Atomic relaxations= Off 
 Electron impact ionization= Off 
 Photon cross sections= xcom 
 Photon cross-sections output= Off  
 
 :Stop MC Transport Parameter: 
 ######################### 
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A.3. DOSRZnrc Input for the Dose to Detector 
 The final stage of the simulations used DOSRZnrc to score the dose to a simulated detector.  
Note that the input is structured rather differently to the preceding inputs, being for a different 
system.  The geometrical inputs section specifies the structure and media of the simulation 
environment.  I/O control specifies the voxels to which dose should be scored, which are chosen 
to correspond to the active volumes.  Geometric data on the detectors was supplied by the 
manufacturers with the condition of a non-disclosure agreement.  Media are assigned to voxels by 
range, with subsequent assignment overwriting earlier specifications as necessary.   DOSRZnrc 
includes the functionality to terminate the simulation before all histories are run if a target 
uncertainty is achieved.  These quantities are specified under Monte Carlo inputs.   The call for 
particle inputs from a phase space file is again ISOURC = 21, with the phase space output by the 
second phase.  The transport settings and VRT options are specified at the end of the input [59]. 
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TITLE= dosrznrc_template—dose to ptwe detector 
 
########################## 
:start I/O control: 
 
IWATCH= off 
STORE INITIAL RANDOM NUMBERS= no 
IRESTART= first 
STORE DATA ARRAYS= yes 
OUTPUT OPTIONS= short 
ELECTRON TRANSPORT= normal 
DOSE ZBOUND MIN= 6 
DOSE ZBOUND MAX= 9 
DOSE RBOUND MIN= 0 
DOSE RBOUND MAX= 1 
 
:stop I/O control: 
######################### 
########################## 
:start Monte Carlo inputs: 
 
NUMBER OF HISTORIES= 15000000000 
INITIAL RANDOM NO. SEEDS= 26, 67 
MAX CPU HOURS ALLOWED= 999 
IFULL= dose and stoppers 
STATISTICAL ACCURACY SOUGHT= 0.500 
SCORE KERMA= no 
 
:stop Monte Carlo inputs: 
######################### 
########################## 
:start geometrical inputs: 
 
METHOD OF INPUT= individual 
Z OF FRONT FACE= 0.0 
DEPTH BOUNDARIES= 25.0, 34.924, 34.953, 34.954, 34.98, 34.985, 35.015, 35.02, 35.084, 
35.252, 35.61, 35.745, 35.885, 36.55, 40, 50 
RADII= 0.0655, 0.075, 0.18, 0.2375, 0.2616, 0.275, 0.2812, 0.345, 20 
MEDIA= AIR521ICRU, 
 H2O521ICRU, 
 RW3521ICRU, 
 AL521ICRU, 
 POLYETH521ICRU, 
 FR4521ICRU, 
 EPOXY521, 
 SI521ICRU, 
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 COAX521;  
DESCRIPTION BY= planes 
MEDNUM= 1, 2, 3, 4, 5, 6, 7, 8, 9, 4, 4 
START ZSLAB= 1, 2, 3, 4, 5, 5, 5, 6, 5, 11, 11 
STOP ZSLAB= 2, 16, 14, 4, 14, 9, 8, 8, 11, 14, 14 
START RING= 1, 1, 1, 1, 1, 1, 1, 1, 5, 5, 1 
STOP RING= 9, 9, 8, 5, 5, 4, 3, 2, 5, 8, 2 
 
:stop geometrical inputs: 
######################### 
########################## 
:start source inputs: 
 
INCIDENT PARTICLE= all 
SOURCE NUMBER= 21 
SOURCE OPTIONS= 0, 0, 0, 0 
FILSPC= ../BEAM_ion_jaws_mini/04x04_MB_0_090eSource_3444.egsphsp1 
 
:stop source inputs: 
######################### 
########################## 
:start MC transport parameter: 
 
Global ECUT= 0.521 
Global PCUT= 0.001 
Global SMAX= 1e10 
ESTEPE= 0.25 
XImax= 0.5 
Skin depth for BCA= 3 
Boundary crossing algorithm= EXACT 
Electron-step algorithm= PRESTA-II 
Spin effects= on 
Brems angular sampling= KM 
Brems cross sections= BH 
Electron Impact Ionization= On 
Bound Compton scattering= On 
Pair angular sampling= Simple 
Photoelectron angular sampling= On 
Rayleigh scattering= Off 
Atomic relaxations= On 
Set PCUT= 0 
Set PCUT start region= 1 
Set PCUT stop region= 1 
Set ECUT= 0 
Set ECUT start region= 1 
Set ECUT stop region= 1 
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Set SMAX= 0 
Set SMAX start region= 1 
Set SMAX stop region= 1 
 
:stop MC transport parameter: 
######################### 
########################## 
:start variance reduction: 
 
BREM SPLITTING= off 
NUMBER OF BREMS PER EVENT= 1 
CHARGED PARTICLE RUSSIAN ROULETTE= off 
ELECTRON RANGE REJECTION= on 
ESAVEIN= 2.0 
RUSSIAN ROULETTE DEPTH= 0.0000 
RUSSIAN ROULETTE FRACTION= 0.0000 
EXPONENTIAL TRANSFORM C= 0.0000 
PHOTON FORCING= off 
START FORCING= 1 
STOP FORCING AFTER= 1 
CS ENHANCEMENT FACTOR= 1 
CS ENHANCEMENT START REGION= 1, 1 
CS ENHANCEMENT STOP REGION= 1, 1 
 
:stop variance reduction: 
######################### 
########################## 
:start plot control: 
 
PLOTTING= off 
 
:stop plot control: 
######################### 
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APPENDIX B 
PERMISSION TO REPRODUCE FIGURES 
Figure 1.1. 
Original image was Figure 5.5 (b) from Chapter 5 “Treatment machines for external beam 
radiotherapy” of Podgorsak E B 2005. Radiation Oncology Physics: A Handbook for Teachers 
and Students. IAEA. Vienna, Austria. [3] 
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Figure 3.3. 
Original image was Figure 3 from Beddar, A S, Mason D J, and O’Brien P F 1994. Absorbed dose 
perturbation caused by diodes for small field photon dosimetry. Medical Physics, 21(7) pp. 1075-
1079. [65] 
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Figure 5.6. 
Original image was Figure 1 from Almond P R, Biggs P J, Coursey B M, Hanson W F, Huq M S, 
Nath R, and Rogers DWO 1999. AAPM's TG-51 protocol for clinical reference dosimetry of high-
energy photon and electron beams. Medical Physics, 26(9), pp. 1847-1870. [34] 
  
126 
 
LIST OF REFERENCES 
[1] Joiner M and van der Kogel A, 2009. Basic Clinical Radiobiology. Fourth Edition. Hodder 
Arnold. London, England. 
[2] Balagamwala E H, Chao S T, and Suh J H 2012. Principles of Radiobiology of Stereotactic 
Radiosurgery and Clinical Applications in the Central Nervous System. Technology in Cancer 
Research and Treatment, 11(1). 
[3] Podgorsak E B 2005. Radiation Oncology Physics: A Handbook for Teachers and Students. 
IAEA. Vienna, Austria. 
[4] Marks H 1952. Clinical Experience with Irradiation Through a Grid. Radiology. 58(3), pp. 338-
342. 
[5] Mohiuddin M, Curtis D L, Grizos W T, and Komarnicky L 1990. Palliative Treatment of 
Advanced Cancer Using Multiple Nonconfluent Pencil Beam Radiation: A Pilot Study. Cancer, 
66(1), pp. 1159-1170. 
[6] Mohiuddin M, Fujita M, Regine W F, Megooni A S, Ibbott G S, and Ahmed M M 1999. High-
dose spatially-factionated radiation (GRID): a new paradigm in the management of advanced 
cancers. International Journal of Radiation Oncology, 45(3), pp. 721-727. 
[7] Ha J K, Zhang G, Naqvi S A, Regine W F, Yu C X 2006, Feasibility of delivering grid therapy 
using a multileaf collimator. Medical Physics, 33(1), pp. 76-82.   
[8] Neuner G, Mohiuddin M D, Walde N V, Goloubeva O, Ha J, Yu C X, and Regine W F 2012. 
High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment 
outcomes with cerroben vs MLC SFGRT. International Journal of Radiation Oncology, 82(5), pp. 
1642-1649. 
[9] Slatkin D N, Spanne P, Dilmanian F A, and Sandborg M 1992. Microbeam Radiotherapy. 
Medical Physics. 19(6), pp 1395-1400. 
[10] Slatkin D N, Spanne P, Dilmanian F A, Gebbers J O, and Laissue J A 1995. Subacute 
neuropathic effects of microplanar beams of x-rays from a synchrotron wiggler. Proceedings of 
the National Academy of Sciences of the United States of America. 92(19), pp. 8783-8787. 
[11] Brauer-Krisch E, Serduc R, Siegbahn E A, Le Duc G, Prezado Y, Bravin A, Blattmann H, 
and Laissue J A, 2010. Effects of pulsed, spatially fractionated, microscopic synchrotron X-ray 
beams on normal and tumoral brain tissue. Mutation Research, 704(1-3), pp 160-166. 
[12] Laissue J et al. 1998. Neuropathology of ablation of rat gliosarcomas and contiguous brain 
tissues using a microplanar beam of synchrotron-wiggler-generated X rays. International Journal 
of Cancer, 78(5), pp. 654-660. 
[13] Dilmanian F A, et al. 2006. Interlace x-ray microplanar beams: A radiosurgery approach with 
clinical potential. Proceedings of the National Academy of Sciences of the United States of 
America, 103(25), pp. 9709-9714. 
127 
 
[14] Regnard P et al., 2008. Irradiation of intracerebral 9L gliosarcoma by a single array of 
microplanar x-ray beams from a synchrotron: blance between curing and sparing. Physics in 
Medicine and Biology, 53(4), pp. 861-878. 
[15] Serduc R et al., 2009. Synchrotron microbeam radiation therapy for rat brain tumor palliation 
- influence of the microbeam width at constant valley dose. Physics in Medicine and Biology, 
54(21), pp. 6711-6724. 
[16] Bouchet A et al., 2010. Preferential effect of sunchrotron microbeam radiation therapy on 
intracerebral 9L gliosarcoma vascular networks. International Journal of Radiation Oncology, 
78(5), pp. 1503-1512. 
[17] Crosbie J C et al., 2010. Tumor cell response to synchrotron microbeam radiation therapy 
differs markedly from cells in normal tissues. International Journal of Radiation Oncology 
Biology Physics, 77(3), pp 886-894. 
[18] Romanelli P and Bravin A 2011. Synchrotron-generated microbeam radiosurgery: a novel 
experimental approach to modulate brain function. Neurological Research, 33(8), pp. 825-831. 
[19] Dilmanian F A et al., 2002. Response of rat intracranial 9L gliosarcoma to microbeam 
radiation therapy. Neuro-Oncology, 4(1), pp. 26-30. 
[20] Deman P et al. 2012. Monochromatic Minibeams Radiotherapy: From Healthy Tissue Sparing 
Studies Toward First Experimental Clioma Bearing Rats Study. International Journal of Radiation 
Oncology, 82(4), pp. e693-e700. 
[21] Prezado Y, Deman P, Varlet P, Jouvion G, Gil S, Le Clec’H C, Bernard H, Le Duc G, and 
Sarun S 2015. Tolerance to Dose Escalation in Minibeam Radiation Therapy Applied to Normal 
Rat Brain: Long Term Clinical, Radiological and Histopathological Analysis. Radiation Research, 
184(3), pp. 314-321 
[22] Babcock K, Sidhu N, Kundapur V, and Ali K 2011. Collimator design for experimental 
minibeam radiation therapy. Medical Physics, 38(4), pp. 2192-2197. 
[23] Cranmer-Sargison G, Crewson C, Davis W, Sidhu N, and Kundapur V, 2015. Medical linear 
accelerator mounted mini-beam collimator: design, fabrication, and dosimetric characterization. 
Physics in Medicine and Biology, 60(17), pp. 6991-7005. 
[24] Podgorsak E B 2010. Radiation Physics for Medical Physicists. 2nd Edition. Springer. Berlin, 
Germany. 
[25] Seltzer S M, Bartlett D T, Burns D T, Dietze G, Menzel H G, Paretzke H G, and Wambersie 
A 2011. Fundamental Quantities and Units for Ionizing Radiation (Revised). Journal of the ICRU, 
11(1). 
[26] Griffiths D J 1999. Introduction to Electrodynamics. 3rd Edition. Pearson. Upper Saddle 
River, NJ, United States. 
128 
 
[27] Evans R D 1955. The Atomic Nucleus. McGraw-Hill Inc. New York, NY, United States. 
[28] Storm E and Israel H 1970. Photon Cross Sections for 1 keV to 100 MeV for Elements Z=1 
to Z=100. Nuclear Data Tables, A7, pp. 565-681. 
[29] Rangacharyulu C 2013. Physics of Nuclear Radiations: Concepts, Techniques and 
Applications. CRC Press. Boca Raton, FL, United States.  
[30] Attix F H 1991. Introduction to Radiological Physics and Radiation Dosimetry. 1st Edition. 
Wiley-VCH. Hoboken, NJ, United States.  
[31] Hirayama H 2000. Lecture Note on Photon Interactions and Cross Sections. High Energy 
Accelerator Research Organization. Oho, Japan.   
[32] Klein O and Nishina Y Z 1929. Über die Streuung von Strahlung durch freie Elektronen 
nach der neuen relativistischen Quantendynamik von Dirac. Zeitschrift für Physik, 52(11), 853-
868. 
[33] Johns H E and Cunningham J R 1983. The Physics of Radiology. 4th Edition. Charles C 
Thomas. Springfield, IL, United States. 
[34] Almond P R, Biggs P J, Coursey B M, Hanson W F, Huq M S, Nath R, and Rogers DWO 
1999. AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon and electron 
beams. Medical Physics, 26(9), pp. 1847-1870. 
[35] Kase K R, Bjärngard B E, and Attix F H 1985. The Dosimetry of Ionizing Radiation. Volume 
1. Academic Press Inc. Orlando, FL, United States. 
[36] Metcalfe P, Kron T, and Hoban P 1997. The Physics of Radiotherapy X-Rays from Linear 
Accelerators. Medical Physics Publishing. Madison, WI United States. 
[37] Gray L H 1936. An Ionization Method for the Absolute Measurement of γ-Ray Energy. 
Proceedings of the Royal Society A, 156(889), pp. 578-596. 
[38] Spencer L V and Attix F H. 1955. A theory of cavity ionization. Radiation Research, 3(3), 
pp. 239-254. 
[39] Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, and Baldock C 2014. Advances in 
kilovoltage x-ray beam dosimetry. Physics in Medicine and Biology, 59(6), pp. 183-231. 
[40] Seco J, Clasie B, and Partridge M 2014. Review on the characteristics of radiation detectors 
for dosimetry and imaging. Physics in Medicine and Biology, 59(20), pp. 303-347. 
[41] Ma C et al. 2001. AAPM protocol for 40-300 kV x-ray dosimetry in radiotherapy and 
radiobiology. Medical Physics, 28(6), pp. 868-897. 
 
129 
 
[42] Andreo P, Burns D T, Hohlfeld K, Huq M S, Kanai T, Laitano F, Smythe V G, and Vynckier 
S 2000. Absorbed Dose Determination in External Beam Radiotherapy: An International Code of 
Practice for Dosimetry Based on Standards of Absorbed Dose to Water. International Atomic 
Energy Agency. Vienna, Austria. 
[43] Huq M S, Andreo P, and Song H 2001. Comparison of the IAEA TRS-398 and AAPM TG-
51 absorbed dose to water protocols in the dosimetry of high-energy photon and electron beams. 
Physics in Medicine and Biology, 46(11), pp. 2985-3006. 
[44] Fraass B, Doppke K, Hunt M, Kutcher G, Starkschall G, Stern R, and Van Dyke J 1998. 
American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: 
Quality assurance for clinical radiotherpay treatment planning. Medical Physics, 25(10), pp. 1773-
1828. 
[45] JCGM/WG 1, 2008. JCGM 100:2008 Evaluation of measurement data – Guide to the 
expression of uncertainty in measurement. Joint Committee for Guides in Metrology. Paris, 
France. 
[46] Nelson W R, Hirayama, H, and Rogers D W O 1985. SLAC-265: The EGS4 Code System. 
National Technical Information Service. Springfield, VT, United States. 
[47] Bielajew A. 2006. The Monte Carlo Simulation of Radiation Transport. University of 
Michigan. Ann Arbor, MI, United States. 
[48] Metropolis N and Ulam S 1949. The Monte Carlo Method. Journal of the American Statistical 
Association, 44(247), pp. 335-341. 
[49] Lyons L 1986. Statistics for nuclear and particle physicists. Press Syndicate of the University 
of Cambridge. Cambridge, England. 
[50] Sobol I M 1974. The Monte Carlo Method. University of Chicago Press. Chicago, IL, United 
States. 
 [51] Chetty I J et al. 2007. Report of the AAPM Task Group No. 105: Issues associated with 
clinical implementation of Monte Carlo-based photon and electron external beam treatment 
planning. Medical Physics, 34(12), pp. 4818-4853. 
[52] Berger M J 1963. Monte Carlo calculation of the penetration and diffusion of fast particles. 
Methods in Computational Physics, 1, pp. 135-215. 
[53] Kawrakow I, Mainegra-Hing E, Rogers D W O, Tessier F, and Walters B R B 2013. The 
EGSnrc Code System: Monte Carlo Simulation of Electron and Photon Transport. NRCC Report 
PIRS-701. National Research Council of Canada. Ottawa, Canada. 
[54] Jenkins T M, Nelson W R, and Rindi A 1988. Monte Carlo Transport of Electrons and 
Photons. Plenum Press. New York, NY, United States. 
130 
 
[55] Seco J and Verhaegen F 2013. Monte Carlo Techniques in Radiation Therapy. CRC Press. 
Boca Raton, FL, United States. 
[56] Rogers D W O, Walters B, and Kawrakow I 2016. BEAMnrc Users Manual. NRCC Report 
PIRS-0509(A)revL. National Research Council of Canada. Ottawa, Canada. 
[57] Rogers D W O, Faddegon B A, Ding G X, Ma C-M, and We J 1995. BEAM: A Monte Carlo 
code to simulate radiotherapy treatment units. Medical Physics, 22(5), pp. 503-524. 
[58] Walters B, Kawrakow I, and Rogers D W O 2016. DOSXYZnrc Users Manual. NRCC Report 
PIRS-794revB. National Research Council of Canada. Ottawa, Canada. 
[59] Rogers D W O, Kawrakow I, Seuntjens J P, Walters B R B, and Mainegra-Hing E 2016. NRC 
User Codes for EGSnrc. NRCC Report PIRS-702(revC). National Research Council of Canada. 
Ottawa, Canada. 
[60] Aspradakis M M, Byrne J P, Palmans H, Conway J, Rosser K, Warrington A P, and Duane S 
2010. Small Field MV Photon Dosimetry: IPEM Report Number 103. Institute of Physics and 
Engineering in Medicine. York, UK. 
[61] Burlin T E 1966.  A general theory of cavity ionisation.  British Journal of Radiology, 39, pp. 
727-734. 
[62] Klein E E et al. 2009. Task Group 142 report: quality assurance of medical accelerators. 
Medical Physics, 36(9), pp. 4197-4212. 
[63] Das I J, Ding G X, and Ahnesjö A 2007. Small fields: Nonequillibrium radiation dosimetry. 
Medical Physics, 35(1), pp. 206-215. 
[64] Cranmer-Sargison G, Charles P H, Trapp J V, and Thwaites D I, 2013. A methodological 
approach to reporting corrected small field relative outputs. Radiotherapy and Oncology, 109(3), 
pp. 350-355. 
[65] Beddar, A S, Mason D J, and O’Brien P F 1994. Absorbed dose perturbation caused by diodes 
for small field photon dosimetry. Medical Physics, 21(7) pp. 1075-1079.  
[66] Babcock K, Cranmer-Sargison G, and Sidhu N 2008. Increasing the speed of DOSXYZnrc 
Monte Carlo simulations through the introduction of nonvoxelated geometries. Medical Physics, 
35(2), pp. 633-644. 
[67] Cranmer-Sargison G, Weston S, Evans J A, Sidhu N P, and Thwaites D I 2011. Implementing 
a newly proposed Monte Carlo based small field dosimetry formalism for a comprehensive set of 
diode detectors. Medical Physics, 38(12), pp. 6592-6602. 
 
131 
 
[68] Cranmer-Sargison G, Weston S, Evans J A, Sidhu N P, and Thwaites D I 2012. Monte Carlo 
modelling of diode detectors for samm field MV photon dosimetry: detector model simplification 
and the sensitivity of correction factors to source paramterization. Physics in Medicine and 
Biology, 57(16), pp. 5141-5153. 
[69] Scott A J D, Kumar S, Nahum A E, and Fenwick J D 2012. Characterizing the influence of 
detector density on dosimeter response in non-equilibrium small photon fields.. Physics in 
Medicine and Biology, 57(14), pp. 4461-4476. 
[70] Moignier C, Huet C, and Makovicka L 2014.  Determination of the kQclin,Qmsr
fclin,fmsr correction 
factors for detectors used with an 800 MU/min CyberKnife system equipped with fixed collimators 
and a study of detector response to small photon beams using a Monte Carlo method. Medical 
Physics, 41(7), pp. 071702. 
[71] Alfonso R  et al. 2008. A new formalism for reference dosimetry of small and non-standard 
fields. Medical Physics, 35(11), pp. 5177-5186. 
[72] Smith S, Davis W, Kundapur V, Moiseenko V, Anderson D, and Cranmer-Sargison G 2015. 
Poster: Cellular Response to High Energy Mini-Beam Radiation. 2015 Annual Saskatchewan 
Cancer Research Conference. Saskatoon, Canada. 
[73] Alexander A, Crewson C, Davis W, Mayer M, Cranmer-Sargison G, and Kundapur V 2016. 
Presentation: Design to delivery of spatially fractionated mini-beam canine radiotherapy. 2016 
COMP Annual Scientific Meeting. St. John’s, Canada.  
 
